

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 July 2001 (26.07.2001)

PCT

(10) International Publication Number  
**WO 01/53342 A1**

(51) International Patent Classification<sup>7</sup>: **C07K 14/47,**  
A61K 47/48, A61P 35/00

**H., Michael** [US/US]; 6 Meyers Court, Novato, CA 94947 (US).

(21) International Application Number: PCT/US01/01362

(74) Agents: **GASHLER, Andrea, L.** et al.; Campbell & Flores LLP, 7th floor, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).

(22) International Filing Date: 16 January 2001 (16.01.2001)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:  
09/489,582 21 January 2000 (21.01.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 09,489,582 (CIP)  
Filed on 21 January 2000 (21.01.2000)

(71) Applicant (*for all designated States except US*): **THE BURNHAM INSTITUTE** [US/US]; 10901 N. Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **RUOSLAHTI, Erkki, I.** [US/US]; P.O. Box 1054, Rancho Santa Fe, CA 92067 (US). **PASQUALINI, Renata** [BR/US]; 7171 Buffalo Speedway #328, Houston, TX 77025 (US). **ARAP, Wadiah** [BR/US]; 7171 Buffalo Speedway #328, Houston, TX 77025 (US). **BREDESEN, Dale, E.** [US/US]; 19 Racoon Drive #1C, Novato, CA 94949 (US). **ELLERBY,**

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/53342 A1

(54) Title: CHIMERIC PROSTATE-HOMING PEPTIDES WITH PRO-APOPTOTIC ACTIVITY

(57) Abstract: The present invention provides a chimeric prostate-homing peptide with pro-apoptotic activity. In a preferred embodiment, the chimeric prostate-homing pro-apoptotic peptide contains the sequence SMSIARL-GG-D(KLAKLAK)<sub>2</sub>. Methods of using such chimeric peptides for treating patients having prostate cancer also are provided.

**CHIMERIC PROSTATE-HOMING PEPTIDES WITH  
PRO-APOPTOTIC ACTIVITY**

This work was supported by grants CA74238, CA28896 and CA30199 from the National Cancer Institute (USA), and by grant DAMD17-98-1-8581 from the Department of Defense. The United States government has certain rights in this invention.

**BACKGROUND OF THE INVENTION**

**FIELD OF THE INVENTION**

10           The present invention relates generally to the fields of cancer biology and drug delivery and, more specifically, to the selective targeting of antimicrobial peptides to the prostate.

**BACKGROUND INFORMATION**

15           Prostatic adenocarcinoma recently became the most frequent cancer diagnosed in American men, surpassing the frequency of lung cancer for the first time. An estimated 30,000 American men die annually of this malignancy. Furthermore, prostate cancer affects  
20 men throughout the world, with the highest frequencies reported in the United States and Scandinavian countries and a moderately high frequency seen throughout Europe. Prostate cancer is a disease of elderly men, and of all patients with this disease, 75% are 60 to 80 years of  
25 age. At the age of 50 years, the estimated lifetime probability of developing clinically apparent prostatic carcinoma is about 10% for American men. However, autopsy studies have shown that the true frequency of

prostatic carcinoma is actually considerably higher than is indicated by clinical evidence.

A major hurdle to advances in treating cancers such as cancer of the prostate is the relative lack of agents that can selectively target the cancer, while sparing normal tissue. For example, radiation therapy and surgery, which generally are localized treatments, can cause substantial damage to normal tissue in the treatment field, resulting in scarring and, in severe cases, loss of function of the normal tissue. Chemotherapy, which generally is administered systemically, can cause substantial damage to organs such as bone marrow, mucosae, skin and the small intestine, which undergo rapid cell turnover and continuous cell division. As a result, undesirable side effects, for example, nausea, hair loss and reduced blood cell counts, occur as a result of systemically treating a cancer patient with chemotherapeutic agents. Such undesirable side effects often limit the amount of a treatment that can be administered. Due to such shortcomings in treatment, cancer remains a leading cause of patient morbidity and death.

Potent antimicrobial activity has been observed for a class of peptides including naturally occurring peptides such as melittin, the gramicidins, magainins, defensins and cecropins. Naturally occurring antimicrobial peptides, and related synthetic antimicrobial sequences, generally have an equivalent number of polar and nonpolar residues within an amphipathic domain and a sufficient number of basic residues to give the peptide an overall positive charge at neutral pH. The biological activity of amphipathic  $\alpha$ -helical peptides against Gram-positive bacteria may

result from the ability of these peptides to form ion channels through membrane bilayers. Many antimicrobial peptides selectively inhibit and kill bacteria while maintaining low mammalian cell cytotoxicity, with the differential sensitivity of bacterial cells apparently due to membrane differences between bacteria and mammalian cells. As shown herein, these antimicrobial peptides can be endowed with selective cytotoxic activity against a particular eukaryotic cell type, such as the endothelium of the prostate gland.

Thus, there is a need for novel anti-cancer therapeutics that can selectively target the prostate. The present invention satisfies this need by providing prostate-homing pro-apoptotic peptides that combine an antimicrobial peptide with a prostate-homing peptide to produce a conjugate with selective toxicity against the prostate. Related advantages are provided as well.

#### SUMMARY OF THE INVENTION

The present invention provides a chimeric prostate-homing pro-apoptotic peptide that contains a prostate-homing peptide linked to an antimicrobial peptide, where the chimeric peptide is selectively internalized by prostate tissue and exhibits high toxicity thereto, while the antimicrobial peptide has low mammalian cell toxicity when not linked to the prostate-homing peptide. In a chimeric peptide of the invention, the prostate-homing peptide portion can contain, for example, the sequence SMSIARL (SEQ ID NO: 207) or a functionally equivalent sequence, and the antimicrobial peptide portion can have an amphipathic  $\alpha$ -helical structure such as the sequence (KLAKLAK)<sub>2</sub> (SEQ ID NO: 200), (KLAKKLA)<sub>2</sub> (SEQ ID NO: 201), (KAAKKAA)<sub>2</sub> (SEQ

ID NO: 202) or (KLGKKLG)<sub>3</sub> (SEQ ID NO: 203). In a preferred embodiment, the antimicrobial peptide portion contains the sequence <sub>D</sub>(KLAKLAK)<sub>2</sub>. An exemplary prostate-homing pro-apoptotic peptide is provided herein as SMSIARL-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>. The present invention further provides a method of directing an antimicrobial peptide to a prostate cancer *in vivo*. The method includes the step of administering a chimeric prostate-homing pro-apoptotic peptide that contains a prostate-homing peptide linked to an antimicrobial peptide, where the chimeric peptide is selectively internalized by prostate tissue and exhibits high toxicity thereto, while the antimicrobial peptide has low mammalian cell toxicity when not linked to the prostate-homing peptide. In a method of the invention, the prostate-homing peptide can contain, for example, the sequence SMSIARL (SEQ ID NO: 207) or a functionally equivalent sequence, and the antimicrobial peptide can contain a sequence such as <sub>D</sub>(KLAKLAK)<sub>2</sub>. In a preferred embodiment, the chimeric prostate-homing pro-apoptotic peptide includes the sequence SMSIARL-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>.

Also provided by the invention is a method of inducing selective toxicity in a prostate cancer *in vivo*. The method includes the step of administering to a subject having prostate cancer a chimeric prostate-homing pro-apoptotic peptide that contains a prostate-homing peptide linked to an antimicrobial peptide, where the chimeric peptide is selectively internalized by prostate tissue and exhibits high toxicity thereto, while the antimicrobial peptide has low mammalian cell toxicity when not linked to the prostate-homing peptide. The method of inducing selective toxicity in a prostate cancer *in vivo* can be practiced, for example, with a prostate-homing peptide containing the sequence SMSIARL

(SEQ ID NO: 207) or a functionally equivalent sequence. The antimicrobial peptide can include, for example, the sequence  $_D(KLAKLAK)_2$ . In a preferred embodiment, the chimeric prostate-homing pro-apoptotic peptide includes  
5 the sequence SMSIARL-GG- $_D(KLAKLAK)_2$ .

In addition, the invention provides a method of treating a patient having prostate cancer by administering to the patient a chimeric prostate-homing pro-apoptotic peptide of the invention, whereby the  
10 chimeric peptide is selectively toxic to the tumor. The chimeric peptide contains a prostate-homing peptide linked to an antimicrobial peptide, and the chimeric peptide is selectively internalized by prostate tissue and exhibits high toxicity thereto, while the  
15 antimicrobial peptide has low mammalian cell toxicity when not linked to the prostate-homing peptide. The prostate-homing peptide portion can contain, for example, the sequence SMSIARL (SEQ ID NO: 207) or a functionally equivalent sequence, and the antimicrobial peptide  
20 portion can contain, for example, the sequence  $_D(KLAKLAK)_2$ . In a preferred embodiment, the chimeric peptide contains the sequence SMSIARL-GG- $_D(KLAKLAK)_2$ .

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 shows a computer-generated model and  
25 amino acid sequence of CNGRC-GG- $_D(KLAKLAK)_2$ , designated "HPP-1."

Upper panel: CNGRC-GG- $_D(KLAKLAK)_2$  (HPP-1) is composed of a homing domain and a membrane-disrupting domain joined by a coupling domain.

Lower panel: Amino acid sequence of "HPP-1" corresponding to the structure shown in upper panel.

Figure 2 shows mitochondrial swelling and mitochondria-dependent apoptosis in the presence of  
5  $\text{D}(\text{KLAKLAK})_2$ .

a. Mitochondrial swelling curve (optical absorbance spectrum) is shown in the presence of  $\text{D}(\text{KLAKLAK})_2$  or  $\text{Ca}^{+2}$  (positive control).

b. Immunoblot of caspase-3 cleavage showing  
10 the 32 kDa proform and 8 and 20 kDa processed forms in the presence of  $\text{D}(\text{KLAKLAK})_2$  or DLSLARLATARLAI (SEQ ID NO: 204) in the presence or absence of mitochondria. Typical experiments are shown. Results were reproduced in three independent experiments.

15 Figure 3 shows mitochondrial swelling and apoptosis in dermal microvessel endothelial cells treated with CNGRC-GG- $\text{D}(\text{KLAKLAK})_2$  (HPP-1).

a. Dermal microvessel endothelial cell cord formation, scale bar = 250  $\mu\text{m}$ .

20 b. DEVD-pNA hydrolysis (caspase activation) in proliferating dermal microvessel endothelial cells treated with CNGRC-GG- $\text{D}(\text{KLAKLAK})_2$  (HPP-1).

c. Viability of proliferating dermal microvessel endothelial cells treated with HPP-1 (black  
25 bars) or control peptide  $\text{D}(\text{KLAKLAK})_2$  (gray bars) over time. (t test,  $P < 0.05$ ).

d. Viability of cord-forming dermal microvessel endothelial cells treated with HPP-1 (black bars) or control peptide  $\text{D}(\text{KLAKLAK})_2$  (gray bars) over time.  
30 (t test,  $P < 0.05$ ).

Figure 4 shows the effect of HPP-1 treatment of nude mice bearing human MDA-MB-435-derived breast carcinoma xenografts.

a. Tumor volume of HPP-1 treated tumors as compared to control CARAC-GG- $\text{D}$ (KLAKLAK) $_2$  treated tumors. Differences in tumor volumes between day 1 and day 50 are shown (t test,  $P=0.027$ ).

b. Kaplan-Meier survival plot showing the survival of nude mice bearing human MDA-MB-435-derived breast carcinoma xenografts treated with HPP-1 or control peptide (mixture of  $\text{D}$ (KLAKLAK) $_2$  and CNGRC (SEQ ID NO: 8). Each group was comprised of thirteen animals. (Log-Rank Test,  $P < 0.05$ ).

Figure 5 shows the effect of CDCRGDCFC-GG- $\text{D}$ (KLAKLAK) $_2$  on oxygen-induced retinal neovascularization in newborn mice. Retinal neovessel number is shown for treatments with vehicle (black bar); CDCRGDCFC-GG- $\text{D}$ (KLAKLAK) $_2$  (striped bar); and a control mixture of unconjugated CDCRGDCFC (SEQ ID NO: 1) and  $\text{D}$ (KLAKLAK) $_2$  (hatched bar).

Figure 6 shows accumulation of intravenously injected biotin conjugate of prostate-homing peptide in prostate tissue. a. Avidin-peroxidase staining of a prostate section from a mouse injected with biotin-labeled prostate homing peptide, SMSIARL (SEQ ID NO: 207). b. Avidin-peroxidase staining of a prostate section from a mouse injected with biotin-labeled control peptide CARAC (SEQ ID NO: 208).

Figure 7 shows apoptosis induced by SMSIARL-GG- $\text{D}$ (KLAKLAK) $_2$  in the normal mouse prostate. a. TUNEL staining of prostate tissue from a mouse treated with SMSIARL-GG- $\text{D}$ (KLAKLAK) $_2$  chimeric peptide. b. Larger



magnification of a field similar to that in a. c. TUNEL staining of negative control mice treated with 250 µg of an unconjugated mixture of SMSIARL (SEQ ID NO: 207) and  $\text{D}(\text{KLAKLAK})_2$ .

5                    Figure 8 shows survival of TRAMP mice treated with SMSIARL-GG- $\text{D}(\text{KLAKLAK})_2$ , vehicle alone,  $\text{D}(\text{KLAKLAK})_2$  peptide alone, or SMSIARL peptide (SEQ ID NO: 207) alone.

                    Figure 9 shows binding of prostate-homing SMSIARL (SEQ ID NO: 207) phage to human prostate  
10 vasculature. a and b. Peroxidase staining of human prostate tissue section containing both normal and cancerous tissue overlaid with  $10^9$  TU SMSIARL phage (SEQ ID NO: 207) and detected with anti-phage antibody. a is an overview (x 20) while b shows a detail from panel a at  
15 a higher magnification (x 40). c. Peroxidase staining as in panel a with phage lacking a peptide insert. d. Peroxidase staining as in a with soluble SMSIARL peptide SEQ ID NO: 207 included in the overlay.

#### DETAILED DESCRIPTION OF THE INVENTION

20                    Antimicrobial peptides, also known as lytic peptides or channel-forming peptides, are broad spectrum anti-bacterial agents. These peptides typically disrupt bacterial cell membranes, causing cell lysis and death. Over 100 antimicrobial peptides occur naturally. In  
25 addition, analogs have been synthesized *de novo* as described in Javadpour et al., J. Med. Chem. 39:3107-3113 (1996); and Blondelle and Houghten, Biochem. 31: 12688-12694 (1992), each of which is incorporated herein by reference. While some antimicrobial peptides such as  
30 melittin are not selective and damage normal mammalian cells at the minimum bactericidal concentration, others

are selective for bacterial cells. For example, the naturally occurring magainins and cecropins exhibit substantial bactericidal activity at concentrations that are not lethal to normal mammalian cells.

5           Antimicrobial peptides frequently contain cationic amino acids, which are attracted to the head groups of anionic phospholipids, leading to the preferential disruption of negatively charged membranes. Once electrostatically bound, the amphipathic helices can  
10 distort the lipid matrix, resulting in loss of membrane barrier function (Epand, The Amphipathic Helix CRC Press: Boca Raton (1993); Lugtenberg and van Alphen, Biochim. Biophys. Acta 737:51-115 (1983), each of which is incorporated herein by reference). Prokaryotic  
15 cytoplasmic membranes maintain large transmembrane potentials and have a high content of anionic phospholipids. In contrast, the outer leaflet of eukaryotic plasma membranes generally has low, or no, membrane potential and is almost exclusively composed of  
20 zwitterionic phospholipids. Thus, due to distinct membrane compositions, antimicrobial peptides can preferentially disrupt prokaryotic membranes as compared to eukaryotic membranes.

          The present invention is directed to the  
25 surprising discovery that an antimicrobial peptide sequence can be linked to a tumor homing molecule to produce a homing pro-apoptotic conjugate that generally is non-toxic outside of eukaryotic cells but which promotes disruption of mitochondrial membranes and  
30 subsequent cell death when targeted and internalized by eukaryotic cells. Homing pro-apoptotic conjugates such as HPP-1, which contains the antimicrobial peptide  $D(KLAKLAK)_2$  linked to the cyclic tumor homing molecule

CNGRC (SEQ ID NO: 8), can have selective toxicity against angiogenic endothelial cells *in vivo* and, thus, be useful as a new class of anti-cancer therapeutics.

Thus, the present invention provides a homing  
5 pro-apoptotic conjugate, which includes a tumor homing molecule that selectively homes to a selected mammalian cell type or tissue linked to an antimicrobial peptide, where the conjugate is selectively internalized by the mammalian cell type or tissue and exhibits high toxicity  
10 thereto, and where the antimicrobial peptide has low mammalian cell toxicity when not linked to the tumor homing molecule. For example, a homing pro-apoptotic conjugate of the invention can exhibit selective toxicity against angiogenic endothelial cells and can be useful,  
15 for example, in methods of inducing selective toxicity *in vivo* in a tumor having angiogenic vasculature.

As disclosed herein, a synthetic antimicrobial peptide with selective toxicity against bacteria as compared to eukaryotic cells,  $_D(KLAKLAK)_2$ , induced marked  
20 mitochondrial swelling at a concentration of 10  $\mu M$  (Figure 2a), significantly less than the concentration required to kill eukaryotic cells, indicating that  $_D(KLAKLAK)_2$  preferentially disrupts mitochondrial membranes as compared to eukaryotic membranes (see  
25 Example I). Moreover,  $_D(KLAKLAK)_2$  activated mitochondria-dependent cell-free apoptosis as measured by characteristic caspase-3 processing (Figure 2b) while a non- $\alpha$ -helix forming peptide DLSLARLATARLAI (SEQ ID NO: 204) did not. These results indicate that  
30 antimicrobial peptides such as  $_D(KLAKLAK)_2$  can disrupt mitochondrial membranes, which, like bacterial membranes, have a high content of anionic phospholipids, reflecting the common ancestry of bacteria and mitochondria (Epan,

*supra*, 1993; Lugtenberg and van Alphen, *supra*, 1983; Matsuzaki et al., Biochemistry 34:6521-6526 (1995); Hovius et al., FEBS Lett. 330:71-76 (1993); and Baltcheffsky and Baltcheffsky in Lee et al., Mitochondria and Microsomes Addison-Wesley: Reading, MA (1981), each of which is incorporated herein by reference).

As further disclosed herein, the antimicrobial peptide  $_D(KLAKLAK)_2$  was conjugated to the cyclic tumor homing peptide CNGRC (SEQ ID NO: 8) via a glycylglycine bridge to produce the peptide CNGRC-GG- $_D(KLAKLAK)_2$ , designated "HPP-1." As disclosed herein, HPP-1 was tested in a tissue culture model of angiogenesis by assaying cord formation, which is a form of migration indicated by a change in endothelial cell morphology from the usual "cobblestones" to chains or cords of cells. Treatment of normal human dermal microvessel cells (DMECs) with 60  $\mu$ M HPP-1 led to a decrease in percent viability with time under the conditions of proliferation (Figure 3c) or cord formation (Figure 3d), while treatment with untargeted  $_D(KLAKLAK)_2$  peptide led to only a negligible loss in viability (see Example II). Furthermore, as shown in Table 1, the  $LC_{50}$  for proliferating or migrating DMECs treated with HPP-1 was an order of magnitude lower than the  $LC_{50}$  for angiostatic DMECs maintained in a monolayer at 100% confluency, demonstrating preferential killing by HPP-1 under angiogenic conditions. The results disclosed herein further demonstrate that the mitochondria of DMECs treated for 24 hours with  $_D(KLAKLAK)_2$  remained morphologically normal, while those treated with CNGRC-GG- $_D(KLAKLAK)_2$  or ACDCRGDCFC-GG- $_D(KLAKLAK)_2$  displayed altered mitochondrial morphology before exhibiting the classical morphological indicators of apoptosis including nuclear condensation and fragmentation.

As shown in Example III, the HPP-1 peptide CNGRC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> also has activity *in vivo*. As disclosed in Figures 4a and b, nude mice bearing human MDA-MD-435 breast carcinoma xenografts were treated with HPP-1. Tumor volume was smaller on average by one order of magnitude, and survival longer in the HPP-1 treated animal groups as compared to control groups. Furthermore, some of the HPP-1 treated mice outlived control mice by several months, indicating that both primary tumor growth and metastasis were inhibited. Destruction of tumor architecture and widespread cell death was evident upon histopathological analysis of the tumors, with about 50% apoptotic cell death. HPP-1 also was effective against tumors derived from the human melanoma cell line C8161; and ACDCRGDCFC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> was effective against MDA-MD-435 breast carcinoma tumors. In sum, these results indicate that homing pro-apoptotic peptides based on tumor homing and antimicrobial peptide sequences can be non-toxic outside of eukaryotic cells but can promote disruption of mitochondrial membranes and subsequent cell death when internalized by the targeted eukaryotic target cells. Homing pro-apoptotic peptides such as HPP-1, which have selective toxicity against angiogenic endothelial cells, can be particularly valuable as anti-cancer therapeutics.

Further results disclosed herein show that retinal neovascularization can be selectively inhibited by a homing pro-apoptotic conjugate of the invention. In particular, the number of retinal neovessels in mice treated with the homing pro-apoptotic conjugate CDCRGDCFC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> was reduced to 30-40% of control levels (see Figure 5). Thus, a homing pro-apoptotic conjugate of the invention can contain a tumor homing molecule, or can contain another homing molecule that

selectively homes to a selected mammalian cell type or tissue.

A homing pro-apoptotic conjugate of the invention is characterized by being highly toxic to the mammalian cell type in which it is internalized. As used herein, the term "highly toxic" means that the conjugate is relatively effective in resulting in cell death of a selected cell type or tissue. One skilled in the art understands that toxicity can be analyzed using one of a variety of well known assays for cell viability. In general, the term highly toxic is used to refer to a conjugate in which the concentration for half maximal killing ( $LC_{50}$ ) is less than about 100  $\mu M$ , preferably less than about 50  $\mu M$ . For example, as disclosed herein, the homing pro-apoptotic conjugate HPP-1 was characterized by  $LC_{50}$ s of 51, 34 and 42, respectively, for angiogenic proliferating and cord forming DMEM cells and for KS1767 cells. Moreover, the prolonged survival of tumor-bearing mice treating with a homing pro-apoptotic conjugate of the invention demonstrates that the selective toxicity can be reproduced *in vivo*.

As used herein, the term "antimicrobial peptide" means a naturally occurring or synthetic peptide having antimicrobial activity, which is the ability to kill or slow the growth of one or more microbes. An antimicrobial peptide can, for example, kill or slow the growth of one or more strains of bacteria including a Gram-positive or Gram-negative bacteria, or a fungi or protozoa. Thus, an antimicrobial peptide can have, for example, bacteriostatic or bacteriocidal activity against, for example, one or more strains of *Escherichia coli*, *Pseudomonas aeruginosa* or *Staphylococcus aureus*. While not wishing to be bound by the following, an

antimicrobial peptide can have biological activity due to the ability to form ion channels through membrane bilayers as a consequence of self-aggregation.

An antimicrobial peptide is typically highly  
5 basic and can have a linear or cyclic structure. As discussed further below, an antimicrobial peptide can have an amphipathic  $\alpha$ -helical structure (see U.S. Patent 5,789,542; Javadpour et al., *supra*, 1996; Blondelle and Houghten, *supra*, 1992). An antimicrobial peptide also  
10 can be, for example, a  $\beta$ -strand/sheet-forming peptide as described in Mancheno et al., J. Peptide Res. 51:142-148 (1998).

An antimicrobial peptide can be a naturally occurring or synthetic peptide. Naturally occurring  
15 antimicrobial peptides have been isolated from biological sources such as bacteria, insects, amphibians and mammals and are thought to represent inducible defense proteins that can protect the host organism from bacterial infection. Naturally occurring antimicrobial peptides  
20 include the gramicidins, magainins, mellitins, defensins and cecropins (see, for example, Maloy and Kari, Biopolymers 37:105-122 (1995); Alvarez-Bravo et al., Biochem. J. 302:535-538 (1994); Bessalle et al., FEBS 274:151-155 (1990); and Blondelle and Houghten in Bristol  
25 (Ed.), Annual Reports in Medicinal Chemistry pages 159-168 Academic Press, San Diego, each of which is herein incorporated by reference). As discussed further below, an antimicrobial peptide also can be an analog of a natural peptide, especially one that retains or  
30 enhances amphipathicity.

An antimicrobial peptide incorporated within a homing pro-apoptotic conjugate of the invention has low mammalian cell toxicity when not linked to a tumor homing molecule. Mammalian cell toxicity readily can be  
5 assessed using routine assays. For example, mammalian cell toxicity can be assayed by lysis of human erythrocytes *in vitro* as described in Javadpour et al., *supra*, 1996. An antimicrobial peptide having "low mammalian cell toxicity" is not lytic to human  
10 erythrocytes or requires concentrations of greater than 100  $\mu$ M for lytic activity, preferably concentrations greater than 200, 300, 500 or 1000  $\mu$ M.

In a preferred embodiment, the invention also provides a homing pro-apoptotic conjugate in which the  
15 antimicrobial peptide portion promotes disruption of mitochondrial membranes when internalized by eukaryotic cells. In particular, such an antimicrobial peptide preferentially disrupts mitochondrial membranes as compared to eukaryotic membranes. Mitochondrial  
20 membranes, like bacterial membranes but in contrast to eukaryotic plasma membranes, have a high content of negatively charged phospholipids. An antimicrobial peptide can be assayed for activity in disrupting mitochondrial membranes using, for example, an assay for  
25 mitochondrial swelling (as described in Example I) or another assay well known in the art. As disclosed herein, for example,  $\text{p(KLAKLAK)}_2$  induced marked mitochondrial swelling at a concentration of 10  $\mu$ M, significantly less than the concentration required to  
30 kill eukaryotic cells. An antimicrobial peptide that induces significant mitochondrial swelling at, for example, 50  $\mu$ M, 40  $\mu$ M, 30  $\mu$ M, 20  $\mu$ M, 10  $\mu$ M, or less, is considered a peptide that promotes disruption of mitochondrial membranes.



The invention also provides a homing pro-apoptotic conjugate in which a tumor homing molecule is linked to an antimicrobial peptide having an amphipathic  $\alpha$ -helical structure. In a homing  
5 pro-apoptotic conjugate of the invention, the antimicrobial peptide portion can have, for example, the sequence (KLAKLAK)<sub>2</sub> (SEQ ID NO: 200); (KLAKKLA)<sub>2</sub> (SEQ ID NO: 201); (KAAKKAA)<sub>2</sub> (SEQ ID NO: 202); or (KLGKKLG)<sub>3</sub> (SEQ ID NO: 203), in particular the sequence <sub>D</sub>(KLAKLAK)<sub>2</sub>. A  
10 homing pro-apoptotic conjugate of the invention can have, for example, the sequence CNGRC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> or ACDCRGDCFC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>.

Antimicrobial peptides generally have random  
15 coil conformations in dilute aqueous solutions, yet high levels of helicity can be induced by helix-promoting solvents and amphipathic media such as micelles, synthetic bilayers or cell membranes.  $\alpha$ -Helical structures are well known in the art, with an ideal  
20  $\alpha$ -helix characterized by having 3.6 residues per turn and a translation of 1.5 Å per residue (5.4Å per turn; see Creighton, Proteins: Structures and Molecular Properties W.H Freeman, New York (1984)). In an amphipathic  $\alpha$ -helical structure, polar and non-polar amino acid  
25 residues are aligned into an amphipathic helix, which is an  $\alpha$ -helix in which the hydrophobic amino acid residues are predominantly on one face, with hydrophilic residues predominantly on the opposite face when the peptide is viewed along the helical axis.

30 Antimicrobial peptides of widely varying sequence have been isolated, sharing an amphipathic  $\alpha$ -helical structure as a common feature (Saberwal et al., Biochim. Biophys. Acta 1197:109-131 (1994)). Analogs of native peptides with amino acid substitutions predicted

to enhance amphipathicity and helicity typically have increased antimicrobial activity. In general, analogs with increased antimicrobial activity also have increased cytotoxicity against mammalian cells (Maloy et al.,  
5 Biopolymers 37:105-122 (1995)).

As used herein in reference to an antimicrobial peptide, the term "amphipathic  $\alpha$ -helical structure" means an  $\alpha$ -helix with a hydrophilic face containing several polar residues at physiological pH and a hydrophobic face  
10 containing nonpolar residues. A polar residue can be, for example, a lysine or arginine residue, while a nonpolar residue can be, for example, a leucine or alanine residue. An antimicrobial peptide having an amphipathic  $\alpha$ -helical structure generally has an  
15 equivalent number of polar and nonpolar residues within the amphipathic domain and a sufficient number of basic residues to give the peptide an overall positive charge at neutral pH (Saberwal et al., Biochim. Biophys. Acta 1197:109-131 (1994), which is incorporated by reference  
20 herein). One skilled in the art understands that helix-promoting amino acids such as leucine and alanine can be advantageously included in an antimicrobial peptide of the invention (see, for example, Creighton, *supra*, 1984).

25 A variety of antimicrobial peptides having an amphipathic  $\alpha$ -helical structure are well known in the art. Such peptides include synthetic, minimalist peptides based on a heptad building block scheme in which repetitive heptads are composed of repetitive trimers  
30 with an additional residue. Such synthetic antimicrobial peptides include, for example, peptides of the general formula  $[(X_1X_2X_2)(X_1X_2X_2)X_1]_n$  (SEQ ID NO: 205) or  $[(X_1X_2X_2)X_1(X_1X_2X_2)]_n$  (SEQ ID NO: 206), where  $X_1$  is a polar

residue,  $X_2$  is a nonpolar residue; and  $n$  is 2 or 3 (see Javadpour et al., *supra*, 1996. (KLAKLAK)<sub>2</sub> (SEQ ID NO: 200); (KLAKKLA)<sub>2</sub> (SEQ ID NO: 201); (KAAKKAA)<sub>2</sub> (SEQ ID NO: 202); and (KLGKKLG)<sub>3</sub> (SEQ ID NO: 203) are examples of  
5 synthetic antimicrobial peptides having an amphipathic  $\alpha$ -helical structure. Similar synthetic, antimicrobial peptides having an amphipathic  $\alpha$ -helical structure also are known in the art, for example, as described in U.S. Patent No. 5,789,542 to McLaughlin and Becker.

10 Helicity readily can be determined by one skilled in the art, for example, using circular dichroism spectroscopy. Percent  $\alpha$ -helicity can be determined, for example, after measuring molar ellipticity at 222 nm as described in Javadpour et al., *supra*, 1996 (see, also,  
15 McLean et al., Biochemistry 30:31-37 (1991), which is incorporated by reference herein). An amphipathic  $\alpha$ -helical antimicrobial peptide of the invention can have, for example, at least about 20% helicity when assayed in amphipathic media such as 25 mM SDS. One  
20 skilled in the art understands that such an antimicrobial peptide having an amphipathic  $\alpha$ -helical structure can have, for example, at least about 25%, 30%, 35% or 40% helicity when assayed in 25 mM SDS. An antimicrobial peptide having an  $\alpha$ -helical structure can have, for  
25 example, from 25% to 90% helicity; 25% to 60% helicity; 25% to 50% helicity; 25% to 40% helicity; 30% to 90% helicity; 30% to 60% helicity; 30% to 50% helicity; 40% to 90% helicity or 40% to 60% helicity when in assayed in 25 mM SDS. Amphipathicity can readily be determined, for  
30 example, using a helical wheel representation of the peptide (see, for example, Blondelle and Houghten, *supra*, 1994).

The structure of an exemplary homing pro-apoptotic conjugate of the invention, CNGRC-GG-D(KLAKLAK)<sub>2</sub>, is illustrated in Figure 1. As can be seen in Figure 1, the homing domain, CNGRC (SEQ ID NO: 8) is a disulfide-bonded cyclic structure and is coupled to a membrane disrupting domain, D(KLAKLAKKLAKLAK) via a glycylglycine bridge. The D-amino acids in the membrane disrupting, antimicrobial portion of the conjugate can be useful in imparting increased stability upon the conjugate *in vivo*. Furthermore, the membrane disrupting D(KLAKLAKKLAKLAK) portion forms an amphipathic helix. In particular, the lysine residues are aligned on one face of the helix (shown as dark shaded region of helix), while the non-polar leucine and alanine residues are aligned on the opposite (light-shaded) face of the helix.

A homing pro-apoptotic conjugate of the invention can be a chimeric peptide in which the tumor homing molecule is a tumor homing peptide. A homing pro-apoptotic chimeric peptide of the invention can have a variety of lengths, from about 18 amino acids to about fifty amino acids or more. A chimeric peptide of the invention can have, for example, from about 20 to about fifty amino acids, preferably from 20 to 40 amino acids, more preferably from 20 to 30 amino acids. Such a chimeric peptide can have, for example, an upper length of 40, 35, 30, 27, 25 or 21 amino acids. A chimeric peptide of the invention can be linear or cyclic. In a preferred embodiment, a homing pro-apoptotic chimeric peptide of the invention includes a cyclic tumor homing peptide portion.

A homing pro-apoptotic chimeric peptide of the invention also can be a peptidomimetic. As used herein, the term "peptidomimetic" is used broadly to mean a peptide-like molecule that has substantially the activity of the corresponding peptide. Peptidomimetics include chemically modified peptides, peptide-like molecules containing non-naturally occurring amino acids, peptoids and the like, have the selective homing activity and the high toxicity of the peptide from which the peptidomimetic is derived (see, for example, "Burger's Medicinal Chemistry and Drug Discovery" 5th ed., vols. 1 to 3 (ed. M.E. Wolff; Wiley Interscience 1995), which is incorporated herein by reference). For example, D amino acids can be advantageously included in the antimicrobial peptide portion of a chimeric peptide of the invention (see Examples I and II). Peptidomimetics provide various advantages over a peptide, including increased stability during passage through the digestive tract and, therefore, can be advantageously used as oral therapeutics.

In a homing pro-apoptotic conjugate of the invention, a "coupling domain" can be used to link a tumor homing peptide and an antimicrobial peptide and can, for example, impart flexibility to the conjugate as a whole. A coupling domain can be, for example, a glycylglycine linker, alaninylalanine linker or other linker incorporating glycine, alanine or other amino acids. The use of a glycylglycine coupling domain is described in Example II.

30

The vasculature within a tumor generally undergoes active angiogenesis, resulting in the continual formation of new blood vessels to support the growing tumor. Such angiogenic blood vessels are distinguishable

from mature vasculature in that angiogenic vasculature expresses unique endothelial cell surface markers, including the  $\alpha_v\beta_3$  integrin (Brooks, Cell 79:1157-1164 (1994); WO 95/14714, Int. Filing Date November 22, 1994) and receptors for angiogenic growth factors (Mustonen and Alitalo, J. Cell Biol. 129:895-898 (1995); Lappi, Semin. Cancer Biol. 6:279-288 (1995)). Moreover, tumor vasculature is histologically distinguishable from other blood vessels in that tumor vasculature is fenestrated (Folkman, Nature Med. 1:27-31 (1995); Rak et al., Anticancer Drugs 6:3-18 (1995)). Thus, the unique characteristics of tumor vasculature make it a particularly attractive target for anti-cancer therapeutics.

As disclosed herein, tumor homing molecules can bind to the endothelial lining of small blood vessels of tumors. The vasculature within tumors is distinct, presumably due to the continual neovascularization, resulting in the formation of new blood vessels required for tumor growth. The distinct properties of the angiogenic neovasculature within tumors are reflected in the presence of specific markers in endothelial cells and pericytes (Folkman, Nature Biotechnol. 15:510 (1997); Risau, FASEB J. 9:926-933 (1995); Brooks et al., *supra*, 1994); these markers likely are being targeted by the disclosed tumor homing molecules.

The ability of a tumor homing molecule to target the blood vessels in a tumor provides substantial advantages over methods of systemic treatment or methods that directly target the tumor cells. For example, tumor cells depend on a vascular supply for survival and the endothelial lining of blood vessels is readily accessible to a circulating probe. Conversely, in order to reach

solid tumor cells, a therapeutic agent must overcome potentially long diffusion distances, closely packed tumor cells, and a dense fibrous stroma with a high interstitial pressure that impedes extravasation (Burrows  
5 and Thorpe, Pharmacol. Ther. 64:155-174 (1994)).

In addition, where the tumor vasculature is targeted, the killing of all target cells may not be required, since partial denudation of the endothelium can lead to the formation of an occlusive thrombus halting  
10 the blood flow through the entirety of the affected tumor vessel (Burrows and Thorpe, *supra*, 1994). Furthermore, unlike direct tumor targeting, there is an intrinsic amplification mechanism in tumor vasculature targeting. A single capillary loop can supply nutrients to up to  
15 100 tumor cells, each of which is critically dependent on the blood supply (Denekamp, Cancer Metast. Rev. 9:267-282 (1990); Folkman, *supra*, 1997).

As set forth above and exemplified herein, a tumor homing molecule that is selective for the  
20 angiogenic endothelial cells of tumor vasculature can be particularly useful for directing a pro-apoptotic antimicrobial peptide to tumor vasculature, while reducing the likelihood that the pro-apoptotic antimicrobial peptide will have a toxic effect on normal,  
25 healthy organs or tissues. Thus, in one embodiment, the invention provides a homing pro-apoptotic conjugate, which includes a tumor homing molecule that selectively homes to angiogenic endothelial cells linked to an antimicrobial peptide, where the conjugate is selectively  
30 internalized by angiogenic endothelial cells and exhibits high toxicity thereto, and where the antimicrobial peptide has low mammalian cell toxicity when not linked to the tumor homing molecule.

As used herein, the term "selective toxicity" means enhanced cell death in a selected cell type or tissue as compared to a control cell type or tissue. In general, selective toxicity is characterized by at least a two-fold greater extent of cell death in the selected cell type or tissue, such as angiogenic endothelial cells, as compared to a control cell type or tissue, for example, angiostatic endothelial cells. Thus, as used herein, the term selective toxicity encompasses specific toxicity, whereby cell death occurs essentially only the selected cell type or tissue, as well as toxicity occurring in a limited number of cell types or tissues in addition to the selected cell type or tissue. One skilled in the art further understands that the term selective toxicity refers to cell death effected by all mechanisms including apoptotic and necrotic cell death. Thus, a homing pro-apoptotic conjugate of the invention that exhibits selective toxicity for angiogenic endothelial cells effects enhanced cell death of the angiogenic endothelial cells as compared to angiostatic endothelial cells or surrounding cells of other types.

As disclosed herein, identified tumor homing molecules are useful for targeting a desired antimicrobial peptide, which is linked to the homing molecule, to a selected cell type such as angiogenic endothelial cells. After being internalized by the angiogenic endothelial cells in tumor vasculature, the antimicrobial peptide is toxic to the endothelial cells, thereby restricting the blood supply to the tumor and inhibiting tumor growth.



A tumor homing molecule useful in the homing pro-apoptotic conjugates of the invention can be a peptide containing, for example, an NGR motif, such as CNGRC (SEQ ID NO: 8); NGRAHA (SEQ ID NO: 6) or  
5 CNGRCVSGCAGRC (SEQ ID NO: 3). A tumor homing molecule useful in the invention also can contain an RGD motif and can be, for example, CDCRGDCFC (SEQ ID NO: 1), or can contain a GSL motif, such as the peptide CGSLVRC (SEQ ID NO: 5). Additional tumor homing molecules can be  
10 identified by screening a library of molecules by *in vivo* panning as set forth in further detail below (see, also, Examples IV to VIII; United States Patent No. 5,622,699, issued April 22, 1997; and Pasqualini and Ruoslahti, Nature 380:364-366 (1996), each of which is incorporated  
15 herein by reference).

The term "tumor homing molecule," as used herein, means an organic chemical such as a drug; a nucleic acid molecule; a peptide or peptidomimetic or protein that selectively homes *in vivo* to a selected cell  
20 type or tissue. By "selectively homes" is meant that, *in vivo*, the tumor homing molecule binds preferentially to a selected cell type or tissue as compared to a control cell type, tissue or organ and generally is characterized by at least a two-fold greater localization at the  
25 selected cell type or tissue compared to a control cell type or tissue. A tumor homing molecule useful in the invention can be, for example, a molecule that binds preferentially to the endothelial cells of angiogenic vasculature as compared to other cell types or  
30 angiostatic vasculature.

Tumor homing molecules were identified using *in vivo* panning as follows. By panning *in vivo* against a breast carcinoma, a melanoma and a Kaposi's sarcoma, phage expressing various peptides that selectively homed to tumors were identified (see Tables 2, 3 and 4, respectively). Due to the large size of the phage (900-1000 nm) and the short time the phage were allowed to circulate (3 to 5 min), it is unlikely that a substantial number of phage would have exited the circulatory system, particularly in the brain and kidney. Tissue staining studies indicated that the tumor homing molecules that were identified primarily homed to and bound endothelial cell surface markers, which likely are expressed in an organ-specific manner. These results indicate that *in vivo* panning can be used to identify and analyze endothelial cell specificities. Such an analysis is not possible using endothelial cells in culture because the cultured cells tend to lose their tissue-specific differences (Pauli and Lee, Lab. Invest. 58:379-387 (1988)).

Although the conditions under which the *in vivo* pannings were performed identified tumor homing peptides that generally bind to endothelial cell markers, the specific presence of phage expressing tumor homing peptides also was observed in tumor parenchyma, particularly at later times after administration of the peptides (Example VII). These results demonstrate that phage expressing peptides can pass through the blood vessels in the tumor, possibly due to the fenestrated nature of the blood vessels, and indicate that the *in vivo* panning method can be useful for identifying target molecules expressed by tumor cells, as well as target molecules expressed by endothelial cells.

Phage peptide display libraries were constructed essentially as described in Smith and Scott (*supra*, 1993; see, also, Koivunen et al., Biotechnology 13:265-270 (1995); Koivunen et al., Meth. Enzymol. 245:346-369 (1994b), each of which is incorporated herein by reference). Oligonucleotides encoding peptides having substantially random amino acid sequences were synthesized based on an "NNK" codon, wherein "N" is A, T, C or G and "K" is G or T. "NNK" encodes 32 triplets, which encode the twenty amino acids and an amber STOP codon (Scott and Smith, *supra*, 1990). In some libraries, at least one codon encoding cysteine also was included in each oligonucleotide so that cyclic peptides could be formed through disulfide linkages (Example IV). The oligonucleotides were inserted in frame with the sequence encoding the gene III protein (gIII) in the vector fuse 5 such that a peptide-gIII fusion protein was expressed. Following expression, the fusion protein was expressed on the surface of the phage containing the vector (Koivunen et al., *supra*, 1994b; Smith and Scott, *supra*, 1993).

Following *in vivo* panning, the phage isolated based on their ability to selectively home to human breast carcinoma, mouse melanoma or human Kaposi's sarcoma tumors displayed only a few different peptide sequences (see Tables 2, 3 and 4, respectively). One of the screenings revealed peptide sequences that contained the arginine-glycine-aspartic acid (RGD) integrin recognition sequence (Ruoslahti, Ann. Rev. Cell Devel. Biol. 12:697 (1996)) in the context of a peptide previously demonstrated to bind selectively to  $\alpha_v$ -containing integrins (Koivunen et al., *supra*, 1995; WO 95/14714). The sequences of most of the remaining tumor homing peptides did not reveal any significant similarities with known ligands for endothelial cell

receptors. However, one of the tumor homing peptides contained the asparagine-glycine-arginine (NGR) motif, which is a weak integrin binding motif similar to the motifs present in integrin-binding peptides (Ruoslahti et al., U.S. Patent No. 5,536,814, issued July 16, 1996, which is incorporated herein by reference; see, also, Koivunen et al., *supra*, 1994a). Other screenings have revealed numerous NGR-containing peptides (see Table 2). Despite the weak integrin binding ability of NGR peptides, an integrin receptor may not be the target molecule recognized by the NGR tumor homing peptides exemplified herein. As used herein, the term "integrin" means a heterodimeric cell surface adhesion receptor.

The peptides expressed by the phage that homed to the breast tumor included the peptides CGRECPRLCQSSC (SEQ ID NO: 2) and CNGRCVSGCAGRC (SEQ ID NO: 3; see Table 2; Example V). Similarly, tumor homing peptides, including the peptides CDCRGDCFC (SEQ ID NO: 1) and CGSLVRC (SEQ ID NO: 5), were identified from two other phage libraries administered to breast tumor bearing mice (Table 2). Some of these motifs, as well as novel ones, also were isolated by screening against mouse melanoma and human Kaposi's sarcoma (see Tables 3 and 4). These results demonstrated that tumor homing molecules can be identified using *in vivo* panning.

Three main tumor homing motifs that were identified can be particularly useful in the homing pro-apoptotic conjugates of the invention. Homing pro-apoptotic conjugates in which the tumor homing molecule portion contains an NGR motif, RGD motif or GSL motif, can be used to target a linked antimicrobial peptide to the endothelial cells of angiogenic vasculature.

In one embodiment, the invention provides a homing pro-apoptotic conjugate, which includes a tumor homing peptide containing the sequence NGR linked to an antimicrobial peptide. In such a homing pro-apoptotic conjugate of the invention, the tumor homing peptide can be, for example, CNGRC (SEQ ID NO: 8); NGRAHA (SEQ ID NO: 6) or CNGRCVSGCAGRC (SEQ ID NO: 3). In a preferred embodiment, the homing pro-apoptotic conjugate includes the sequence CNGRC-GG-D(KLAKLAK)<sub>2</sub>.

10 In another embodiment, the invention provides a homing pro-apoptotic conjugate, which includes a tumor homing peptide containing the sequence RGD linked to an antimicrobial peptide. In such a homing pro-apoptotic conjugate, the tumor homing peptide can be, for example, CDCRGDCFC (SEQ ID NO: 1). In a preferred embodiment, the homing pro-apoptotic conjugate includes the sequence ACDCRGDCFC-GG-D(KLAKLAK)<sub>2</sub>.

The invention additionally provides a homing pro-apoptotic conjugate, which includes a tumor homing peptide containing the sequence GSL linked to an antimicrobial peptide. In such a homing pro-apoptotic conjugate, the tumor homing peptide can be, for example, CGSLVRC (SEQ ID NO: 5).

As discussed above, one motif contained the sequence RGD (Ruoslahti, *supra*, 1996) embedded in the peptide structure, CDCRGDCFC (SEQ ID NO: 1), which is known to bind selectively to  $\alpha_v$  integrins (Koivunen et al., *supra*, 1995; WO 95/14714). Since the  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins are markers of angiogenic vessels (Brooks et al., *supra*, 1994; Friedlander et al., *Science* 270:1500 (1995)), a phage expressing the peptide CDCRGDCFC (SEQ ID NO: 1) was examined for tumor targeting and, as disclosed

herein, homed to tumors in a highly selective manner (see Example VI). Furthermore, homing by the CDCRGDCFC (SEQ ID NO: 1) phage was inhibited by coadministration of the free CDCRGDCFC (SEQ ID NO: 1) peptide.

- 5                   Another breast tumor homing peptide had the sequence CNGRCVSGCAGRC (SEQ ID NO: 3), which contains the NGR motif previously shown to have weak integrin binding activity (Koivunen et al., J. Biol. Chem. 268:20205-20210 (1993); Koivunen et al., *supra*, 1994a; WO 95/14714).
- 10 Since an NGR containing peptide was identified, two additional peptides, the linear peptide, NGRAHA (SEQ ID NO: 6), and the cyclic peptide, CVLNGRMEC (SEQ ID NO: 7), each of which contains the NGR motif, were examined for tumor homing. Like the phage expressing CNGRCVSGCAGRC
- 15 (SEQ ID NO: 3), phage expressing NGRAHA (SEQ ID NO: 6) or CVLNGRMEC (SEQ ID NO: 7) homed to the tumors. Furthermore, tumor homing was not dependent on the tumor type or on species, as the phage accumulated selectively in human breast carcinoma, as well as in the tumors of
- 20 mice bearing a mouse melanoma and mice bearing a human Kaposi's sarcoma xenograft.

- The various peptides, including RGD- and NGR-containing peptides, generally were bound to the tumor blood vessels. The minimal cyclic NGR peptide,
- 25 CNGRC (SEQ ID NO: 8), was synthesized based on the CNGRCVSGCAGRC (SEQ ID NO: 3) sequence. When the CNGRC (SEQ ID NO: 8) peptide was co-injected with phage expressing either CNGRCVSGCAGRC (SEQ ID NO: 3), NGRAHA (SEQ ID NO: 6) or CVLNGRMEC (SEQ ID NO: 7), accumulation
- 30 of the phage in the breast carcinoma xenografts was inhibited. However, the CNGRC (SEQ ID NO: 8) peptide did not inhibit the homing of phage expressing the CDCRGDCFC (SEQ ID NO: 1) peptide, even when administered in amounts

up to ten times higher than those that inhibited the homing of the NGR phage. In comparison, the CDCRGDCFC (SEQ ID NO: 1) peptide partially inhibited the homing of the NGR phage, although the amount needed was 5 to 10 fold higher than that of the CNGRC peptide (SEQ ID NO: 8). These results indicate that NGR peptides and RGD peptides bind to different receptor sites in tumor vasculature.

A third motif, GSL (glycine-serine-leucine), also was identified following *in vivo* panning in mice bearing breast carcinoma, malignant melanoma or Kaposi's sarcoma. Homing of phage expressing the GSL peptide, CGSLVRC (SEQ ID NO: 5), was inhibited by coadministration of the free CGSLVRC (SEQ ID NO: 5) peptide. Like the RGD and NGR peptides, phage expressing GSL peptides also bound to blood vessels of tumors. In view of the identification of the conserved RGD, NGR and GSL motifs present in tumor homing peptides, as disclosed herein, it will be recognized that peptides containing such motifs can be useful as tumor homing peptides and, in particular, for forming homing pro-apoptotic conjugates that can selectively deliver an antimicrobial peptide to a tumor.

Various peptide libraries containing up to 13 amino acids were constructed, and the NGR peptide, CNGRCVSGCAGRC (SEQ ID NO: 3), was obtained as a result of *in vivo* panning against a breast tumor. This NGR peptide, which was obtained by screening a random peptide library, was a tumor homing peptide. In addition, when a peptide library was constructed based on the formula CXXXNGRXX (SEQ ID NO: 13) or CXXCNGRCX (SEQ ID NO: 14), each of which is biased toward NGR sequences, and used

for *in vivo* panning against a breast tumor, numerous NGR peptides were obtained (see Table 2).

These results indicate that a tumor homing molecule of the invention can comprise the amino acid sequence RGD or NGR or GSL. Such a tumor homing molecule can be a peptide as small as five amino acids, such as CNGRC (SEQ ID NO: 8). Such tumor homing peptides also can be not only at least 13 amino acids in length, which is the largest peptide exemplified herein, but can be up to 20 amino acids, or 30 amino acids, or 50 to 100 amino acids in length, as desired. A tumor homing peptide of the invention conveniently is produced by chemical synthesis.

Immunohistochemical analysis was performed by comparing tissue staining for phage allowed to circulate for about four minutes, followed by perfusion through the heart of the mice, or with tissues analyzed 24 hours after phage injection. At 24 hours following administration, essentially no phage remain in the circulation and, therefore, perfusion is not required (Pasqualini et al., *supra*, 1997). Strong phage staining was observed in tumor vasculature, but not in normal endothelium, in samples examined four minutes after administration of the CNGRCVSGCAGRC (SEQ ID NO: 3) phage (Example VII). In comparison, staining of the tumor was strong at 24 hours and appeared to have spread outside the blood vessels into the tumor parenchyma. The NGRAHA (SEQ ID NO: 6) and CVLNGRMEC (SEQ ID NO: 7) phage showed similar staining patterns (Example VII). In contrast, the control organs and tissues showed little or no immunostaining, confirming the specificity of the NGR motifs for tumor vessels. Spleen and liver, however, captured phage, as expected, since uptake by the



reticuloendothelial system is a general property of phage particles, independent of the presence of peptide expression by the phage (Pasqualini et al., *supra*, 1997).

Immunostaining also was observed following  
5 administration of phage expressing the GSL motif  
containing peptide, CLSGSLSC (SEQ ID NO: 4), and, like  
that of the NGR peptides, was localized to the blood  
vessels, in this case, within a melanoma tumor (see  
below; see, also, Examples VII and VIII). Similarly,  
10 immunostaining following administration of phage  
expressing the RGD motif containing peptide, CDCRGDCFC  
(SEQ ID NO: 1), to breast tumor bearing mice was  
localized to the blood vessels in the tumor, but was not  
observed in brain, kidney or various other nontumor  
15 tissues (see Examples VI and VII; see, also, Pasqualini  
et al., *supra*, 1997). These results demonstrate that the  
various tumor homing peptides generally home to tumor  
vasculature.

The general applicability of the *in vivo*  
20 panning method for identifying tumor homing molecules was  
examined by injecting mice bearing a syngeneic melanoma  
with phage expressing a diverse population of peptides  
(Example VIII). The B16 mouse melanoma model was  
selected for these studies because the tumors that form  
25 are highly vascularized and because the biology of this  
tumor line has been thoroughly characterized (see Miner  
et al., Cancer Res. 42:4631-4638 (1982)). Furthermore,  
because the B16 melanoma cells are of mouse origin,  
species differences between the host and the tumor cell  
30 donor will not affect, for example, the distribution of  
phage into the tumor as compared to into normal organs.  
As disclosed herein, *in vivo* panning against B16 melanoma  
cells revealed tumor homing peptides, including, for

example, the GSL moiety containing peptide CLSGSLSC (SEQ ID NO: 4; see, also, Table 3) and immunohistochemical staining of the tumor and other organs using an anti-phage antibody demonstrated that the CLSGSLSC (SEQ ID NO: 4) expressing phage resulted in immunostaining in the melanoma, but essentially no staining in skin, kidney or other control organs (Example VIII). The staining pattern generally followed the blood vessels within the melanoma, but was not strictly confined to the blood vessels.

Although *in vivo* panning was performed in mice, tumor homing molecules such as peptides comprising an NGR, RGD or GSL motif also likely can target human vasculature. The NGR phage binds to blood vessels in the transplanted human breast tumor, but not to blood vessels in normal tissues, indicating that this motif can be particularly useful for tumor targeting in patients. The CDCRGDCFC (SEQ ID NO: 1) peptide binds to human  $\alpha_v$ -integrins (Koivunen et al., *supra*, 1995), which are selectively expressed in tumor blood vessels of human patients (Max et al., Int. J. Cancer 71:320 (1997); Max et al., Int. J. Cancer 72:706 (1997)). Use of a homing pro-apoptotic conjugate in which CDCRGDCFC (SEQ ID NO: 1) is linked to an antimicrobial peptide provides the additional advantage that the antimicrobial peptide can be targeted to tumor cells, themselves, because breast carcinoma cells, for example, can express the  $\alpha_v\beta_3$  integrin (Pasqualini et al., *supra*, 1997). In fact, many human tumors express this integrin, which may be involved in the progression of certain tumors such as malignant melanomas (Albelda et al., Cancer Res. 50:6757-6764 (1990); Danen et al., Int. J. Cancer 61:491-496 (1995); Felding-Habermann et al., J. Clin. Invest. 89:2018-2022 (1992); Sanders et al., Cold Spring Harb. Symp. Quant.

Biol. 58:233-240 (1992); Mitjans et al., J. Cell. Sci. 108:3067-3078 (1995)). Unlike the CDCRGDCFC (SEQ ID NO: 1) peptide, the NGR peptides do not appear to bind to MDA-MD-435 breast carcinoma cells. However, NGR peptides  
5 were able to deliver a therapeutically effective amount of doxorubicin to breast tumors, indicating that, even where a tumor homing molecule homes only to tumor vasculature, i.e., not directly to the tumor cells, such vasculature targeting is sufficient to confer the effect  
10 of the moiety linked to the molecule.

Since the  $\alpha_v\beta_3$  integrin is expressed by endothelial cells in angiogenic vasculature, experiments were performed to determine whether tumor vasculature that is undergoing angiogenesis can be targeted *in vivo*  
15 using methods as disclosed herein. Phage expressing the peptide, CDCRGDCFC (SEQ ID NO: 1; see, Koivunen et al., *supra*, 1995), which is known to bind to the  $\alpha_v\beta_3$  integrin, were injected into mice bearing tumors formed from human breast carcinoma cells, mouse melanoma cells or human  
20 Kaposi's sarcoma cells (see Example VII). The CDCRGDCFC (SEQ ID NO: 1) phage selectively homed to each of the tumors, whereas such homing did not occur with control phage. For example, in mice bearing tumors formed by implantation of human breast carcinoma cells, a twenty-  
25 to eighty-fold greater number of the CDCRGDCFC (SEQ ID NO: 1) phage, as compared to unselected control phage, accumulated in the tumor.

Tissue staining for the phage showed accumulation of the CDCRGDCFC (SEQ ID NO: 1) phage in the  
30 blood vessels within the tumor, whereas no staining was observed in brain, kidney or other control organs. Specificity of tumor homing by the CDCRGDCFC (SEQ ID NO: 1) phage was demonstrated by competition experiments,

in which coinjection of the free CDCRGDCFC (SEQ ID NO: 1) peptide greatly reduced tumor homing of the RGD phage, whereas coinjection of a non-RGD-containing control peptide had no effect on homing of the RGD phage (see  
5 Example VI). These results demonstrate that the  $\alpha_v\beta_3$  target molecule is expressed on the luminal surface of endothelial cells in a tumor and that a peptide that binds to an  $\alpha_v$ -containing integrin can bind selectively to this integrin and, therefore, to vasculature undergoing  
10 angiogenesis.

The results of these studies indicate that tumor homing molecules can be identified by *in vivo* panning and that, in some cases, a tumor homing molecule can home to vascular tissue in the tumor as well as to  
15 tumor parenchyma, probably due to the fenestrated nature of the blood vessels permitting ready exit of the phage from the circulatory system. Due to the ability of such tumor homing molecules to home to tumors, the molecules are useful for targeting a linked antimicrobial peptide  
20 to tumors. Thus, the invention provides conjugates comprising a tumor homing molecule linked to a moiety, such conjugates being useful for targeting the moiety to tumor cells.

The ability of a molecule that homes to a  
25 particular tumor to selectively home to another tumor of the same or a similar histologic type can be determined using, for example, human tumors grown in nude mice or mouse tumors grown in syngeneic mice for these experiments. For example, various human breast cancer  
30 cell lines, including MDA-MB-435 breast carcinoma (Price et al., Cancer Res. 50:717-721 (1990)), SKBR-1-II and SK-BR-3 (Fogh et al., J. Natl. Cancer Inst. 59:221-226 (1975)), and mouse mammary tumor lines, including EMT6

(Rosen et al., Int. J. Cancer 57:706-714 (1994)) and C3-L5 (Lala and Parhar, Int. J. Cancer 54:677-684 (1993)), are readily available and commonly used as models for human breast cancer. Using such breast tumor  
5 models, for example, information relating to the specificity of an identified breast tumor homing molecule for diverse breast tumors can be obtained and molecules that home to a broad range of different breast tumors or provide the most favorable specificity profiles can be  
10 identified. In addition, such analyses can yield new information, for example, about tumor stroma, since stromal cell gene expression, like that of endothelial cells, can be modified by the tumor in ways that cannot be reproduced *in vitro*.

15                Selective homing of a molecule such as a peptide or protein to a tumor can be due to specific recognition by the peptide of a particular cell target molecule such as a cell surface receptor present on a cell in the tumor. Selectivity of homing is dependent on  
20 the particular target molecule being expressed on only one or a few different cell types, such that the molecule homes primarily to the tumor. As discussed above, the identified tumor homing peptides, at least in part, can recognize endothelial cell surface markers in the blood  
25 vessels present in the tumors. However, most cell types, particularly cell types that are unique to an organ or tissue, can express unique target molecules. Thus, *in vivo* panning can be used to identify molecules that selectively home to a particular type of tumor cell such  
30 as a breast cancer cell; specific homing can be demonstrated by performing the appropriate competition experiments.

As used herein, the term "tumor" means a mass of cells that are characterized, at least in part, by containing angiogenic vasculature. The term "tumor" is used broadly to include the tumor parenchymal cells as well as the supporting stroma, including the angiogenic blood vessels that infiltrate the tumor parenchymal cell mass. Although a tumor generally is a malignant tumor, i.e., a "cancer," a tumor also can be nonmalignant, provided that neovascularization is associated with the tumor. The term "normal" or "nontumor" tissue is used to refer to tissue that is not a "tumor." As disclosed herein, a tumor homing molecule can be identified based on its ability to home a tumor, but not to a corresponding nontumor tissue.

As used herein, the term "corresponding," when used in reference to tumors or tissues or both, means that two or more tumors, or two or more tissues, or a tumor and a tissue are of the same histologic type. The skilled artisan will recognize that the histologic type of a tissue is a function of the cells comprising the tissue. Thus, the artisan will recognize, for example, that a nontumor tissue corresponding to a breast tumor is normal breast tissue, whereas a nontumor tissue corresponding to a melanoma is skin, which contains melanocytes. Furthermore, for purposes of the invention, it is recognized that a tumor homing molecule can bind specifically to a target molecule expressed by the vasculature in a tumor, which generally contains blood vessels undergoing neovascularization, in which case a tissue corresponding to the tumor would comprise nontumor tissue containing blood vessels that are not undergoing active angiogenesis.

A tumor homing molecule useful in the invention can be identified by screening a library of molecules by *in vivo* panning as disclosed herein and set forth in United States Patent No. 5,622,699, issued April 22, 1997; and Pasqualini and Ruoslahti, Nature 380:364-366 (1996), each of which is incorporated herein by reference). As used herein, the term "library" means a collection of molecules. A library can contain a few or a large number of different molecules, varying from about ten molecules to several billion molecules or more. If desired, a molecule can be linked to a tag, which can facilitate recovery or identification of the molecule.

As used herein, the term "molecule" is used broadly to mean a polymeric or non-polymeric organic chemical such as a drug; a nucleic acid molecule such as an RNA, a cDNA or an oligonucleotide; a peptide, including a variant or modified peptide or peptide-like molecules, referred to herein as peptidomimetics, which mimic the activity of a peptide; or a protein such as an antibody or a growth factor receptor or a fragment thereof such as an Fv, Fd or Fab fragment of an antibody, which contains a binding domain. For convenience, the term "peptide" is used broadly herein to mean peptides, proteins, fragments of proteins and the like. A molecule also can be a non-naturally occurring molecule, which does not occur in nature, but is produced as a result of *in vitro* methods, or can be a naturally occurring molecule such as a protein or fragment thereof expressed from a cDNA library.

A tumor homing molecule also can be a peptidomimetic. As used herein, the term "peptidomimetic" is used broadly to mean a peptide-like molecule that has the binding activity of the tumor

homing peptide. With respect to the tumor homing peptides of the invention, peptidomimetics, which include chemically modified peptides, peptide-like molecules containing non-naturally occurring amino acids, peptoids  
5 and the like, have the binding activity of a tumor homing peptide upon which the peptidomimetic is derived (see, for example, "Burger's Medicinal Chemistry and Drug Discovery," *supra*, 1995).

Methods for identifying a peptidomimetic are  
10 well known in the art and include, for example, the screening of databases that contain libraries of potential peptidomimetics. For example, the Cambridge Structural Database contains a collection of greater than 300,000 compounds that have known crystal structures  
15 (Allen et al., Acta Crystallogr. Section B, 35:2331 (1979)). This structural depository is continually updated as new crystal structures are determined and can be screened for compounds having suitable shapes, for example, the same shape as a tumor homing molecule, as  
20 well as potential geometrical and chemical complementarity to a target molecule bound by a tumor homing peptide. Where no crystal structure of a tumor homing peptide or a target molecule that binds the tumor homing molecule is available, a structure can be  
25 generated using, for example, the program CONCORD (Rusinko et al., J. Chem. Inf. Comput. Sci. 29:251 (1989)). Another database, the Available Chemicals Directory (Molecular Design Limited, Informations Systems; San Leandro CA), contains about 100,000  
30 compounds that are commercially available and also can be searched to identify potential peptidomimetics of a tumor homing molecule.



Methods for preparing libraries containing diverse populations of various types of molecules such as peptides, peptoids and peptidomimetics are well known in the art and various libraries are commercially available (see, for example, Ecker and Crooke, Biotechnology 13:351-360 (1995), and Blondelle et al., Trends Anal. Chem. 14:83-92 (1995), and the references cited therein, each of which is incorporated herein by reference; see, also, Goodman and Ro, Peptidomimetics for Drug Design, in "Burger's Medicinal Chemistry and Drug Discovery" Vol. 1 (ed. M.E. Wolff; John Wiley & Sons 1995), pages 803-861, and Gordon et al., J. Med. Chem. 37:1385-1401 (1994), each of which is incorporated herein by reference). Where a molecule is a peptide, protein or fragment thereof, the molecule can be produced *in vitro* directly or can be expressed from a nucleic acid, which can be produced *in vitro*. Methods of synthetic peptide and nucleic acid chemistry are well known in the art.

A library of molecules also can be produced, for example, by constructing a cDNA expression library from mRNA collected from a cell, tissue, organ or organism of interest. Methods for producing such libraries are well known in the art (see, for example, Sambrook et al., Molecular Cloning: A laboratory manual (Cold Spring Harbor Laboratory Press 1989), which is incorporated herein by reference). Preferably, a peptide encoded by the cDNA is expressed on the surface of a cell or a virus containing the cDNA. For example, cDNA can be cloned into a phage vector such as fuse 5 (Example IV), wherein, upon expression, the encoded peptide is expressed as a fusion protein on the surface of the phage.

In addition, a library of molecules can comprise a library of nucleic acid molecules, which can be DNA or RNA or an analog thereof. Nucleic acid molecules that bind, for example, to a cell surface receptor are well known (see, for example, O'Connell et al., Proc. Natl. Acad. Sci., USA 93:5883-5887 (1996); Tuerk and Gold, Science 249:505-510 (1990); Gold et al., Ann. Rev. Biochem. 64:763-797 (1995), each of which is incorporated herein by reference). Thus, a library of nucleic acid molecules can be administered to a subject having a tumor, and tumor homing molecules subsequently identified by *in vivo* panning. If desired, the nucleic acid molecules can be nucleic acid analogs that, for example, are less susceptible to attack by nucleases (see, for example, Jelinek et al., Biochemistry 34:11363-11372 (1995); Latham et al., Nucl. Acids Res. 22:2817-2822 (1994); Tam et al., Nucl. Acids Res. 22:977-986 (1994); Reed et al., Cancer Res. 59:6565-6570 (1990), each of which is incorporated herein by reference).

As set forth herein, *in vivo* panning can be used to identify a tumor homing molecule, which can be linked to an antimicrobial peptide to form a homing pro-apoptotic conjugate of the invention. *In vivo* panning comprises administering a library to a subject, collecting a sample of a tumor and identifying a tumor homing molecule. The presence of a tumor homing molecule can be identified using various methods well known in the art. Generally, the presence of a tumor homing molecule in a tumor is identified based on one or more characteristics common to the molecules present in the library, then the structure of a particular tumor homing molecule is identified. For example, a highly sensitive detection method such as mass spectrometry, either alone

or in combination with a method such as gas chromatography, can be used to identify tumor homing molecules in a tumor. Thus, where a library comprises diverse molecules based generally on the structure of an organic molecule such as a drug, a tumor homing molecule can be identified by determining the presence of a parent peak for the particular molecule.

If desired, the tumor can be collected, then processed using a method such as HPLC, which can provide a fraction enriched in molecules having a defined range of molecular weights or polar or nonpolar characteristics or the like, depending, for example, on the general characteristics of the molecules comprising the library. Conditions for HPLC will depend on the chemistry of the particular molecule and are well known to those skilled in the art. Similarly, methods for bulk removal of potentially interfering cellular materials such as DNA, RNA, proteins, lipids or carbohydrates are well known in the art, as are methods for enriching a fraction containing an organic molecule using, for example, methods of selective extraction. Where a library comprises a population of diverse organic chemical molecules, each linked to a specific oligonucleotide tag, such that the specific molecule can be identified by determining the oligonucleotide sequence using polymerase chain reaction (PCR), genomic DNA can be removed from the sample of the collected tumor in order to reduce the potential for background PCR reactions. In addition, a library can comprise a population of diverse molecules such as organic chemical molecules, each linked to a common, shared tag. Based on the presence and properties of the shared tag, molecules of the library that selectively home to a tumor can be substantially isolated from a sample of the tumor. These and other methods can

be useful for enriching a sample of a collected tumor for the particular tumor homing molecule, thereby removing potentially contaminating materials from the collected tumor sample and increasing the sensitivity of detecting  
5 a molecule.

Evidence provided herein indicates that a sufficient number of tumor homing molecules selectively homes to a tumor during *in vivo* panning such that the molecules readily can be identified. For example,  
10 various independent phage expressing the same peptide were identified in tumors formed from implanted human breast cancer cells (Table 2), from mouse melanoma cells (Table 3) or from human Kaposi's sarcoma cells (Table 4).

Although a substantial fraction of the  
15 identified tumor homing molecules have the same structure, the peptide inserts of only a small number of isolated phage were determined. It should be recognized, however, that hundreds of thousands to millions of phage expressing organ homing peptides have been recovered  
20 following *in vivo* pannings for organ homing molecules (see, for example, U.S. Patent No. 5,622,699; Pasqualini and Ruoslahti, *supra*, 1996). These results indicate that specific tumor homing molecules will be present in substantial numbers in a tumor following *in vivo* homing,  
25 thereby increasing the ease with which the molecules can be identified.

Ease of identification of a tumor homing molecule, particularly an untagged molecule, depends on various factors, including the presence of potentially  
30 contaminating background cellular material. Thus, where the tumor homing molecule is an untagged peptide, a larger number must home to the tumor in order to identify

the specific peptides against the background of cellular protein. In contrast, a much smaller number of an untagged organic chemical homing molecule such as a drug is identifiable because such molecules normally are  
5 absent from or present in only small numbers in the body. In such a case, a highly sensitive method such as mass spectrometry can be used to identify a tumor homing molecule. The skilled artisan will recognize that the method of identifying a molecule will depend, in part, on  
10 the chemistry of the particular molecule.

Where a tumor homing molecule is a nucleic acid molecule or is tagged with a nucleic acid molecule, an assay such as PCR can be particularly useful for identifying the presence of the molecule because, in  
15 principle, PCR can detect the presence of a single nucleic acid molecule (see, for example, Erlich, PCR Technology: Principles and Applications for DNA Amplification (Stockton Press 1989), which is incorporated herein by reference). Preliminary studies  
20 have demonstrated that, following intravenous injection of 10 ng of an approximately 6000 base pair plasmid into a mouse and 2 minutes in the circulation, the plasmid was detectable by PCR in a sample of lung. These results indicate that nucleic acid molecules are sufficiently  
25 stable when administered into the circulation such that *in vivo* panning can be used to identify nucleic acid molecules that selectively home to a tumor.

The molecules of a library can be tagged, which can facilitate recovery or identification of the  
30 molecule. As used herein, the term "tag" means a physical, chemical or biological moiety such as a plastic microbead, an oligonucleotide or a bacteriophage, respectively, that is linked to a molecule of the

library. Methods for tagging a molecule are well known in the art (Hermanson, Bioconjugate Techniques (Academic Press 1996), which is incorporated herein by reference).

A tag, which can be a shared tag or a specific tag, can be useful for identifying the presence or structure of a tumor homing molecule of a library. As used herein, the term "shared tag" means a physical, chemical or biological moiety that is common to each molecule in a library. Biotin, for example, can be a shared tag that is linked to each molecule in a library. A shared tag can be useful to identify the presence of a molecule of the library in a sample and also can be useful to substantially isolate the molecules from a sample. For example, where the shared tag is biotin, the biotin-tagged molecules in a library can be substantially isolated by binding to streptavidin, or their presence can be identified by binding with a labeled streptavidin. Where a library is a phage display library, the phage that express the peptides are another example of a shared tag, since each peptide of the library is linked to a phage. In addition, a peptide such as the hemagglutinin antigen can be a shared tag that is linked to each molecule in a library, thereby allowing the use of an antibody specific for the hemagglutinin antigen to substantially isolate molecules of the library from a sample of a selected tumor.

A shared tag also can be a nucleic acid sequence that can be useful to identify the presence of molecules of the library in a sample or to substantially isolate molecules of a library from a sample. For example, each of the molecules of a library can be linked to the same selected nucleotide sequence, which constitutes the shared tag. An affinity column

containing a nucleotide sequence that is complementary to the shared tag then can be used to hybridize molecules of the library containing the shared tag, thus substantially isolating the molecules from a tumor sample. A

- 5 nucleotide sequence complementary to a portion of the shared nucleotide sequence tag also can be used as a PCR primer such that the presence of molecules containing the shared tag can be identified in a sample by PCR.

- A tag also can be a specific tag. As used  
10 herein, the term "specific tag" means a physical, chemical or biological tag that is linked to a particular molecule in a library and is unique for that particular molecule. A specific tag is particularly useful if it is readily identifiable. A nucleotide sequence that is  
15 unique for a particular molecule of a library is an example of a specific tag. For example, the method of synthesizing peptides tagged with a unique nucleotide sequence provides a library of molecules, each containing a specific tag, such that upon determining the nucleotide  
20 sequence, the identity of the peptide is known (see Brenner and Lerner, Proc. Natl. Acad. Sci., USA 89:5381-5383 (1992), which is incorporated herein by reference). The use of a nucleotide sequence as a specific tag for a peptide or other type of molecule  
25 provides a simple means to identify the presence of the molecule in a sample because an extremely sensitive method such as PCR can be used to determine the nucleotide sequence of the specific tag, thereby identifying the sequence of the molecule linked thereto.  
30 Similarly, the nucleic acid sequence encoding a peptide expressed on a phage is another example of a specific tag, since sequencing of the specific tag identifies the amino acid sequence of the expressed peptide.

The presence of a shared tag or a specific tag can provide a means to identify or recover a tumor homing molecule following *in vivo* panning. In addition, the combination of a shared tag and specific tag can be particularly useful for identifying a tumor homing molecule. For example, a library of peptides can be prepared such that each is linked to a specific nucleotide sequence tag (see, for example, Brenner and Lerner, *supra*, 1992), wherein each specific nucleotide sequence tag has incorporated therein a shared tag such as biotin. Upon homing to a tumor, the particular tumor homing peptides can be substantially isolated from a sample of the tumor based on the shared tag and the specific peptides can be identified, for example, by PCR of the specific tag (see Erlich, *supra*, 1989).

A tag also can serve as a support. As used herein, the term "support" means a tag having a defined surface to which a molecule can be attached. In general, a tag useful as a support is a shared tag. For example, a support can be a biological tag such as a virus or virus-like particle such as a bacteriophage ("phage"); a bacterium such as *E. coli*; or a eukaryotic cell such as a yeast, insect or mammalian cell; or can be a physical tag such as a liposome or a microbead, which can be composed of a plastic, agarose, gelatin or other biological or inert material. If desired, a shared tag useful as a support can have linked thereto a specific tag. Thus, a phage display library, for example, can be considered to consist of the phage, which is a shared tag that also is a support, and the nucleic acid sequence encoding the expressed peptide, the nucleic acid sequence being a specific tag.



In general, a support should have a diameter less than about 10  $\mu\text{m}$  to about 50  $\mu\text{m}$  in its shortest dimension, such that the support can pass relatively unhindered through the capillary beds present in the subject and not occlude circulation. In addition, a support can be nontoxic, so that it does not perturb the normal expression of cell surface molecules or normal physiology of the subject, and biodegradable, particularly where the subject used for *in vivo* panning is not sacrificed to collect a selected tumor.

Where a molecule is linked to a support, the tagged molecule comprises the molecule attached to the surface of the support, such that the part of the molecule suspected of being able to interact with a target molecule in a cell in the subject is positioned so as to be able to participate in the interaction. For example, where the tumor homing molecule is suspected of being a ligand for a growth factor receptor, the binding portion of the molecule attached to a support is positioned so it can interact with the growth factor receptor on a cell in the tumor. If desired, an appropriate spacer molecule can be positioned between the molecule and the support such that the ability of the potential tumor homing molecule to interact with the target molecule is not hindered. A spacer molecule also can contain a reactive group, which provides a convenient and efficient means of linking a molecule to a support and, if desired, can contain a tag, which can facilitate recovery or identification of the molecule (see Hermanson, *supra*, 1996).

As exemplified herein, a peptide suspected of being able to home to a selected tumor such as a breast carcinoma or a melanoma was expressed as the N-terminus of a fusion protein, wherein the C-terminus consisted of a phage coat protein. Upon expression of the fusion protein, the C-terminal coat protein linked the fusion protein to the surface of a phage such that the N-terminal peptide was in a position to interact with a target molecule in the tumor. Thus, a molecule having a shared tag was formed by the linking of a peptide to a phage, wherein the phage provided a biological support, the peptide molecule was linked as a fusion protein, the phage-encoded portion of the fusion protein acted as a spacer molecule, and the nucleic acid encoding the peptide provided a specific tag allowing identification of a tumor homing peptide.

As used herein, the term "in vivo panning," when used in reference to the identification of a tumor homing molecule, means a method of screening a library by administering the library to a subject and identifying a molecule that selectively homes to a tumor in the subject (see U.S. Patent No. 5,622,699). The term "administering to a subject," when used in reference to a library of molecules or a portion of such a library, is used in its broadest sense to mean that the library is delivered to a tumor in the subject, which, generally, is a vertebrate, particularly a mammal such as a human.

A library can be administered to a subject, for example, by injecting the library into the circulation of the subject such that the molecules pass through the tumor; after an appropriate period of time, circulation is terminated by sacrificing the subject or by removing a sample of the tumor (Example IV; see, also, U.S. Patent

No. 5,622,699; Pasqualini and Ruoslahti, *supra*, 1996). Alternatively, a cannula can be inserted into a blood vessel in the subject, such that the library is administered by perfusion for an appropriate period of  
5 time, after which the library can be removed from the circulation through the cannula or the subject can be sacrificed to collect the tumor, or the tumor can be sampled, to terminate circulation. Similarly, a library can be shunted through one or a few organs, including the  
10 tumor, by cannulation of the appropriate blood vessels in the subject. It is recognized that a library also can be administered to an isolated perfused tumor. Such panning in an isolated perfused tumor can be useful to identify molecules that bind to the tumor and, if desired, can be  
15 used as an initial screening of a library.

The use of *in vivo* panning to identify tumor homing molecules is exemplified herein by screening a phage peptide display library in tumor-bearing mice and identifying specific peptides that selectively homed to a  
20 breast tumor or to a melanoma tumor (Example IV). However, phage libraries that display protein receptor molecules, including, for example, an antibody or an antigen binding fragment of an antibody such as an Fv, Fd or Fab fragment; a hormone receptor such as a growth factor  
25 receptor; or a cell adhesion receptor such as an integrin or a selectin also can be used to practice the invention. Variants of such molecules can be constructed using well known methods such as random mutagenesis, site-directed mutagenesis or codon based mutagenesis (see Huse, U.S.  
30 Patent No. 5,264,563, issued November 23, 1993, which is incorporated herein by reference). If desired, peptides can be chemically modified following expression of the phage but prior to administration to the subject. Thus,

various types of phage display libraries can be screened by *in vivo* panning.

Phage display technology provides a means for expressing a diverse population of random or selectively randomized peptides. Various methods of phage display and methods for producing diverse populations of peptides are well known in the art. For example, Ladner et al. (U.S. Patent No. 5,223,409, issued June 29, 1993, which is incorporated herein by reference) describe methods for preparing diverse populations of binding domains on the surface of a phage. In particular, Ladner et al. describe phage vectors useful for producing a phage display library, as well as methods for selecting potential binding domains and producing randomly or selectively mutated binding domains.

Similarly, Smith and Scott (Meth. Enzymol. 217:228-257 (1993); see, also, Scott and Smith, Science 249: 386-390 (1990), each of which is incorporated herein by reference) describe methods of producing phage peptide display libraries, including vectors and methods of diversifying the population of peptides that are expressed (see, also, Huse, WO 91/07141 and WO 91/07149, each of which is incorporated herein by reference; see, also, Example IV). Phage display technology can be particularly powerful when used, for example, with a codon based mutagenesis method, which can be used to produce random peptides or randomly or desirably biased peptides (Huse, U.S. Patent No. 5,264,563, *supra*, 1993). These or other well known methods can be used to produce a phage display library, which can be subjected to *in vivo* panning in order to identify tumor homing molecules useful in the homing pro-apoptotic conjugates of the invention.

In addition to screening a phage display library, *in vivo* panning can be used to screen various other types of libraries, including, for example, an RNA or DNA library or a chemical library. If desired, the tumor homing molecule can be tagged, which can facilitate recovery of the molecule from the tumor or identification of the molecule in the tumor. For example, where a library of organic molecules, each containing a shared tag, is screened, the tag can be a moiety such as biotin, which can be linked directly to the molecule or can be linked to a support containing the molecules. Biotin provides a shared tag useful for recovering the molecule from a selected tumor sample using an avidin or streptavidin affinity matrix. In addition, a molecule or a support containing a molecule can be linked to a hapten such as 4-ethoxy-methylene-2-phenyl-2-oxazoline-5-one (phOx), which can be bound by an anti-phOx antibody linked to a magnetic bead as a means to recover the molecule. Methods for purifying biotin or phOx labeled conjugates are known in the art and the materials for performing these procedures are commercially available (e.g., Invitrogen, La Jolla CA; and Promega Corp., Madison WI). In the case where a phage library is screened, the phage can be recovered using methods as disclosed in Example IV.

*In vivo* panning provides a method for directly identifying tumor homing molecules that can selectively home to a tumor. As used herein, the term "home" or "selectively home" means that a particular molecule binds relatively specifically to a target molecule present in the tumor following administration to a subject. In general, a tumor homing molecule is characterized, in part, by exhibiting at least a two-fold (2x) greater

specific binding to a tumor as compared to a control organ or tissue.

It should be recognized that, in some cases, a molecule can localize nonspecifically to an organ or  
5 tissue containing a tumor. For example, *in vivo* panning of a phage display library can result in high background in organs such as liver and spleen, which contain a marked component of the reticuloendothelial system (RES). Thus, where a tumor is present, for example, in the  
10 liver, nonspecific binding of molecules due to uptake by the RES can make identifying a tumor homing molecule more difficult.

Selective homing of a tumor homing molecule can be distinguished from nonspecific binding, however, by  
15 detecting differences in the abilities of different individual phage to home to a tumor. For example, selective homing can be identified by combining a putative tumor homing molecule such as a peptide expressed on a phage with a large excess of non-infective  
20 phage or with about a five-fold excess of phage expressing unselected peptides, injecting the mixture into a subject and collecting a sample of the tumor. In the latter case, for example, provided the number of injected phage expressing tumor homing peptide is  
25 sufficiently low so as to be nonsaturating for the target molecule, a determination that greater than about 20% of the phage in the tumor express the putative tumor homing molecule is demonstrative evidence that the peptide expressed by the phage is a specific tumor homing  
30 molecule. In addition, nonspecific localization can be distinguished from selective homing by performing competition experiments using, for example, phage expressing a putative tumor homing peptide in combination

with an excess amount of the "free" peptide  
(Example VII).

In addition, various methods can be used to prevent nonspecific binding of a molecule to an organ  
5 containing a component of the RES. For example, a molecule that homes selectively to a tumor present in an organ containing a component of the RES can be obtained by first blocking the RES using, for example, polystyrene latex particles or dextran sulfate (see Kalin et al.,  
10 Nucl. Med. Biol. 20:171-174 (1993); Illum et al., J. Pharm. Sci. 75:16-22 (1986); Takeya et al., J. Gen. Microbiol. 100:373-379 (1977) , each of which is incorporated herein by reference), then administering the library to the subject. For example, pre-administration  
15 of dextran sulfate 500 or polystyrene microspheres prior to administration of a test substance has been used to block nonspecific uptake of the test substance by Kupffer cells, which are the RES component of the liver (Illum et al., *supra*, 1986). Similarly, nonspecific uptake of  
20 agents by the RES has been blocked using carbon particles or silica (Takeya et al., *supra*, 1977) or a gelatine colloid (Kalin et al., *supra*, 1993). Thus, various agents useful for blocking nonspecific uptake by the RES are known and routinely used.

25 Nonspecific binding of phage to RES or to other sites also can be prevented by coinjecting, for example, mice with a specific phage display library together with the same phage made noninfective (Smith et al., *supra*, 1990, 1993). In addition, a peptide that homes to tumor  
30 in an organ containing an RES component can be identified by preparing a phage display library using phage that exhibit low background binding to the particular organ. For example, Merrill et al. (Proc. Natl. Acad. Sci., USA

93:3188-3192 (1996), which is incorporated herein by reference) selected lambda-type phage that are not taken up by the RES and, as a result, remain in the circulation for a prolonged period of time. A filamentous phage  
5 variant, for example, can be selected using similar methods.

Selective homing of a tumor homing molecule can be demonstrated by determining the specificity of a tumor homing molecule for the tumor as compared to a control  
10 organ or tissue. Selective homing also can be demonstrated by showing that molecules that home to a tumor, as identified by one round of *in vivo* panning, are enriched for tumor homing molecules in a subsequent round of *in vivo* panning. For example, phage expressing  
15 peptides that selectively home to a melanoma tumor were isolated by *in vivo* panning, then were subjected to additional rounds of *in vivo* panning. Following a second round of screening, phage recovered from the tumor showed a 3-fold enrichment in homing to the tumor as compared to  
20 brain. Phage recovered from the tumor after a third round of screening showed an average of 10-fold enrichment in homing to the tumor as compared to brain. Selective homing also can be demonstrated by showing that molecules that home to a selected tumor, as identified by  
25 one round of *in vivo* panning, are enriched for tumor homing molecules in a subsequent round of *in vivo* panning.

Tumor homing molecules can be identified by *in vivo* panning using, for example, a mouse containing a  
30 transplanted tumor. Such a transplanted tumor can be, for example, a human tumor that is transplanted into immunodeficient mice such as nude mice or a murine tumor that is maintained by passage in tissue culture or in



mice. Due to the conserved nature of cellular receptors and of ligands that bind a particular receptor, it is expected that angiogenic vasculature and histologically similar tumor cells in various species can share common cell surface markers useful as target molecules for a tumor homing molecule. Thus, the skilled artisan would recognize that a tumor homing molecule identified using, for example, *in vivo* panning in a mouse having a murine tumor of a defined histological type such as a melanoma also would bind to the corresponding target molecule in a tumor in a human or other species. Similarly, tumors growing in experimental animals require associated neovascularization, just as that required for a tumor growing in a human or other species. Thus, a tumor homing molecule that binds a target molecule present in the vasculature in a tumor grown in a mouse likely also can bind to the corresponding target molecule in the vasculature of a tumor in a human or other mammalian subject. The general ability of a tumor homing molecule identified, for example, by homing to a human breast tumor, also to home to a human Kaposi's sarcoma or to a mouse melanoma indicates that the target molecules are shared by many tumors. Indeed, the results disclosed herein demonstrate that the target molecules are expressed in the neovasculature, which is host tissue (see Example VII).

A tumor homing molecule identified using *in vivo* panning in an experimental animal such as a mouse readily can be examined for the ability to bind to a corresponding tumor in a human patient by demonstrating, for example, that the molecule also can bind specifically to a sample of the tumor obtained from the patient. For example, the CDCRGDCFC (SEQ ID NO: 1) phage and NGR peptides have been shown to bind to blood vessels in

microscopic sections of human tumors, whereas little or no binding occurs in the blood vessels of nontumor tissues. Thus, routine methods can be used to confirm that a tumor homing molecule identified using *in vivo* panning in an experimental animal also can bind the target molecule in a human tumor.

The steps of administering the library to the subject, collecting a selected tumor and identifying tumor homing molecules that home to the tumor, comprise a single round of *in vivo* panning. Although not required, one or more additional rounds of *in vivo* panning generally are performed. Where an additional round of *in vivo* panning is performed, the molecules recovered from the tumor in the previous round are administered to a subject, which can be the same subject used in the previous round, where only a part of the tumor was collected.

By performing a second round of *in vivo* panning, the relative binding selectivity of the molecules recovered from the first round can be determined by administering the identified molecules to a subject, collecting the tumor, and determining whether more phage are recovered from the tumor following the second round of screening as compared to those recovered following the first round. Although not required, a control organ or tissue also can be collected and the molecules recovered from the tumor can be compared with those recovered from the control organ. Ideally, no molecules are recovered from a control organ or tissue following a second or subsequent round of *in vivo* panning. Generally, however, a proportion of the molecules also will be present in a control organ or tissue. In this case, the ratio of molecules in the

selected tumor as compared to the control organ  
(selected:control) can be determined. For example, phage  
that homed to melanoma following a first round of *in vivo*  
panning demonstrated a 3x enrichment in homing to the  
5 selected tumor as compared to the control organ, brain,  
following two additional rounds of panning  
(Example VIII).

Additional rounds of *in vivo* panning can be  
used to determine whether a particular molecule homes  
10 only to the selected tumor or can recognize a target on  
the tumor that also is expressed in one or more normal  
organs or tissues in a subject or is sufficiently similar  
to the target molecule on the tumor. It is unlikely that  
a tumor homing molecule also will home to a corresponding  
15 normal tissue because the method of *in vivo* panning  
selects only those molecules that home to the selected  
tumor. Where a tumor homing molecule also directs homing  
to one or more normal organs or tissues in addition to  
the tumor, the organs or tissues are considered to  
20 constitute a family of selected organs or tissues. Using  
the method of *in vivo* panning, molecules that home to  
only the selected tumor can be distinguished from  
molecules that also home to one or more selected organs  
or tissues. Such identification is expedited by  
25 collecting various organs or tissues during subsequent  
rounds of *in vivo* panning.

The term "control organ or tissue" is used to  
mean an organ or tissue other than the tumor for which  
the identification of a tumor homing molecule is desired.  
30 A control organ or tissue is characterized in that a  
tumor homing molecule does not selectively home to the  
control organ. A control organ or tissue can be  
collected, for example, to identify nonspecific binding

of the molecule or to determine the selectivity of homing of the molecule. In addition, nonspecific binding can be identified by administering, for example, a control molecule, which is known not to home to a tumor but is  
5 chemically similar to a potential tumor homing molecule. Alternatively, where the administered molecules are linked to a support, administration of the supports, alone, also can be used to identify nonspecific binding. For example, a phage that expresses the gene III protein,  
10 alone, but that does not contain a peptide fusion protein, can be studied by *in vivo* panning to determine the level of nonspecific binding of the phage support.

As disclosed herein, specific homing of a tumor homing molecule readily can be identified by examining  
15 the selected tumor tissue as compared to a corresponding nontumor tissue, as well as to control organs or tissues. For example, immunohistological analysis can be performed on a tumor tissue and corresponding nontumor tissue using an antibody specific for a phage used to display tumor  
20 homing peptides (see Example VII). Alternatively, an antibody can be used that is specific for a shared tag that is expressed with the peptide, for example, a FLAG epitope or the like, such detection systems being commercially available.

25 In general, a library of molecules, which contains a diverse population of random or selectively randomized molecules of interest, is prepared, then administered to a subject. At a selected time after administration, the subject is sacrificed and the tumor  
30 is collected such that the molecules present in the tumor can be identified (see Example IV). If desired, one or more control organs or tissues or a part of a control organ or tissue can be sampled. For example, mice

bearing a breast tumor or a melanoma tumor were injected with a phage peptide display library, then, after about 1 to 5 minutes, the mice were anesthetized, either frozen in liquid nitrogen or, preferably, are perfused through the heart to terminate circulation of the phage, the tumor and one or more control organs were collected from each, phage present in the tumor and the control organs were recovered and peptides that selectively homed to the respective tumors were identified (see Examples IV, V and VIII).

In the examples provided, the animals were sacrificed to collect the selected tumor and control organ or tissue. It should be recognized, however, that only a part of a tumor need be collected to recover a support containing a tumor homing molecule and, similarly, only part of an organ or tissue need be collected as a control. Thus, a part of a tumor, for example, can be collected by biopsy, such that a molecule such as a peptide expressed by a phage can be administered to the same subject a second time or more, as desired. Where the molecule that is to be administered a second time to the same subject is tagged or linked, for example, to a support, the tag or support should be nontoxic and biodegradable, so as not to interfere with subsequent rounds of screening.

*In vitro* screening of phage libraries previously has been used to identify peptides that bind to antibodies or to cell surface receptors (Smith and Scott, *supra*, 1993). For example, *in vitro* screening of phage peptide display libraries has been used to identify novel peptides that specifically bound to integrin adhesion receptors (Koivunen et al., J. Cell Biol. 124:373-380 (1994a), which is incorporated herein by

reference) and to the human urokinase receptor (Goodson et al., Proc. Natl. Acad. Sci., USA 91:7129-7133 (1994)). However, such *in vitro* studies provide no insight as to whether a peptide that can specifically bind to a  
5 selected receptor *in vitro* also will bind the receptor *in vivo* or whether the binding peptide or the receptor are unique to a specific organ in the body. Furthermore, the *in vitro* methods are performed using defined, well-characterized target molecules in an artificial  
10 system. For example, Goodson et al., *supra*, 1994, utilized cells expressing a recombinant urokinase receptor. However, such *in vitro* methods are limited in that they require prior knowledge of the target molecule and yield little if any information regarding *in vivo*  
15 utility.

*In vitro* panning against cells in culture also has been used to identify molecules that can specifically bind to a receptor expressed by the cells (Barry et al., Nature Med. 2:299-305 (1996), which is incorporated  
20 herein by reference). However, the cell surface molecules that are expressed by a cell *in vivo* often change when the cell is grown in culture. Thus, *in vitro* panning methods using cells in culture also are limited in that there is no guarantee a molecule that is  
25 identified due to its binding to a cell in culture will have the same binding ability *in vivo*. Furthermore, it is not possible to use *in vitro* panning to distinguish molecules that home only to the tumor cells used in the screening, but not to other cell types.

In contrast, *in vivo* panning requires no prior knowledge or availability of a target molecule and identifies molecules that bind to cell surface target molecules that are expressed *in vivo*. Also, since the  
5 "nontargeted" tissues are present during the screening, the probability of isolating tumor homing molecules that lack specificity of homing is greatly reduced. Furthermore, in obtaining tumor homing molecules by *in vivo* panning, any molecules that may be particularly  
10 susceptible to degradation in the circulation *in vivo* due, for example, to a metabolic activity, are not recovered. Thus, *in vivo* panning provides significant advantages over previous methods by identifying tumor homing molecules that selectively home *in vivo* to a  
15 target molecule present in a tumor.

Although mechanisms by which the disclosed method of *in vivo* panning works have not been fully defined, one possibility is that a molecule such as a peptide expressed on a phage recognizes and binds to a  
20 target molecule present on endothelial cells lining the blood vessels in a tumor. Evidence indicates, for example, that the vascular tissues in various organs differ from one another and that such differences can be involved in regulating cellular trafficking in the body.  
25 For example, lymphocytes home to lymph nodes or other lymphoid tissues due, in part, to the expression of specific "address" molecules by the endothelial cells in those tissues (Salmi et al., Proc. Natl. Acad. Sci., USA 89:11436-11440 (1992); Springer, Cell 76:301-314 (1994)).  
30 Similarly, various leukocytes can recognize sites of inflammation due, in part, to the expression of endothelial cell markers induced by inflammatory signals (see Butcher and Picker, Science 272:60-66 (1996);

Springer, *supra*, 1994). Thus, endothelial cell markers provide a potential target that can be selectively bound by a tumor homing molecule and used to direct a linked antimicrobial peptide to a tumor.

5 Additional components can be included as part of the homing pro-apoptotic conjugate, if desired. For example, in some cases, it can be desirable to utilize an oligopeptide spacer between a tumor homing molecule and the antimicrobial peptide. Such spacers are well known  
10 in the art, as described, for example, in Fitzpatrick and Garnett, Anticancer Drug Des. 10:1-9 (1995)).

A homing pro-apoptotic chimeric peptide of the invention can readily be synthesized in required quantities using routine methods of solid state peptide  
15 synthesis. A chimeric peptide of the invention also can be purchased from a commercial source (for example, AnaSpec, Inc.; San Jose, CA). Where an antimicrobial peptide is to be linked to a non-peptide tumor homing molecule, the antimicrobial peptide portion can be  
20 synthesized independently using well known methods or obtained from commercial sources.

Several methods can be used to link an antimicrobial peptide to a tumor homing molecule are known in the art, depending on the particular chemical  
25 characteristics of the molecule. For example, methods of linking haptens to carrier proteins as used routinely in the field of applied immunology (see, for example, Harlow and Lane, *supra*, 1988; Hermanson, *supra*, 1996).



A premade antimicrobial peptide also can be conjugated to a tumor homing peptide using, for example, carbodiimide conjugation (Bauminger and Wilchek, Meth. Enzymol. 70:151-159 (1980), which is incorporated herein  
5 by reference). Carbodiimides comprise a group of compounds that have the general formula  $R-N=C=N-R'$ , where R and R' can be aliphatic or aromatic, and are used for synthesis of peptide bonds. The preparative procedure is simple, relatively fast, and is carried out under mild  
10 conditions. Carbodiimide compounds attack carboxylic groups to change them into reactive sites for free amino groups. Carbodiimide conjugation has been used to conjugate a variety of compounds to carriers for the production of antibodies.

15 The water soluble carbodiimide, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) can be useful for conjugating an antimicrobial peptide to a tumor homing molecule. Such conjugation requires the presence of an amino group, which can be provided, for  
20 example, by an antimicrobial peptide, and a carboxyl group, which can be provided by the tumor homing molecule.

In addition to using carbodiimides for the direct formation of peptide bonds, EDC also can be used  
25 to prepare active esters such as N-hydroxysuccinimide (NHS) ester. The NHS ester, which binds only to amino groups, then can be used to induce the formation of an amide bond with the single amino group of the doxorubicin. The use of EDC and NHS in combination is  
30 commonly used for conjugation in order to increase yield of conjugate formation (Bauminger and Wilchek, *supra*, 1980).

Other methods for conjugating an antimicrobial peptide to a tumor homing molecule also can be used. For example, sodium periodate oxidation followed by reductive alkylation of appropriate reactants can be used, as can  
5 glutaraldehyde crosslinking. However, it is recognized that, regardless of which method of producing a conjugate of the invention is selected, a determination must be made that the tumor homing molecule maintains its targeting ability and that the antimicrobial peptide  
10 maintains its antimicrobial activity. Methods known in the art can confirm the activity of a homing pro-apoptotic conjugate of the invention.

The yield of antimicrobial peptide/tumor homing molecule conjugate formed is determined using routine  
15 methods. For example, HPLC or capillary electrophoresis or other qualitative or quantitative method can be used (see, for example, Liu et al., J. Chromatogr. 735:357-366 (1996); Rose et al., J. Chromatogr. 425:419-412 (1988), each of which is incorporated herein by reference; see,  
20 also, Example VIII). In particular, the skilled artisan will recognize that the choice of a method for determining yield of a conjugation reaction depends, in part, on the physical and chemical characteristics of the specific antimicrobial peptide and tumor homing molecule.  
25 Following conjugation, the reaction products are desalted to remove any free peptide or molecule.

The present invention also provides methods of directing an antimicrobial peptide *in vivo* to a tumor having angiogenic vasculature. The method is practiced  
30 by administering a homing pro-apoptotic conjugate of the invention to a subject containing a tumor having angiogenic vasculature. In a method of the invention for directing an antimicrobial peptide *in vivo* to a tumor

having angiogenic vasculature, the antimicrobial peptide can include, for example, the sequence  $_D(KLAKLAK)_2$ . Particularly useful conjugates that can be administered to a subject containing a tumor having angiogenic

5 vasculature include  $CNGRC-GG-_D(KLAKLAK)_2$  and  $ACDCRGDCFC-GG-_D(KLAKLAK)_2$ .

The present invention additionally provides methods of inducing selective toxicity *in vivo* in a tumor having angiogenic vasculature. The methods are practiced

10 by administering a homing pro-apoptotic conjugate of the invention to a subject containing a tumor having angiogenic vasculature. An antimicrobial peptide useful in inducing selective toxicity in a method of the invention can be, for example, a peptide containing the

15 sequence  $_D(KLAKLAK)_2$ . Particularly useful conjugates that can be administered to induce selective toxicity *in vivo* in a tumor having angiogenic vasculature include  $CNGRC-GG-_D(KLAKLAK)_2$  and  $ACDCRGDCFC-GG-_D(KLAKLAK)_2$ .

Also provided herein are methods of treating a

20 patient with a tumor having angiogenic vasculature. In such methods of treatment, a homing pro-apoptotic conjugate of the invention is administered to the patient and is selectively toxic to the tumor. The antimicrobial peptide portion can include, for example, the sequence

25  $_D(KLAKLAK)_2$ . In preferred embodiments, the homing pro-apoptotic conjugate has the sequence  $CNGRC-GG-_D(KLAKLAK)_2$  or  $ACDCRGDCFC-GG-_D(KLAKLAK)_2$ .

When administered to a subject, a homing pro-apoptotic conjugate of the invention can be

30 administered as a pharmaceutical composition containing, for example, the conjugate and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers

are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil or injectable  
5 organic esters.

A pharmaceutically acceptable carrier can contain physiologically acceptable compounds that act, for example, to stabilize or to increase the absorption of the conjugate. Such physiologically acceptable  
10 compounds include, for example, carbohydrates, such as glucose, sucrose or dextrans; antioxidants, such as ascorbic acid or glutathione; chelating agents; low molecular weight proteins; or other stabilizers or excipients. One skilled in the art would know that the  
15 choice of a pharmaceutically acceptable carrier, including a physiologically acceptable compound, depends, for example, on the route of administration of the composition. The pharmaceutical composition also can contain an agent such as a cancer therapeutic agent.

20 One skilled in the art would know that a homing pro-apoptotic conjugate of the invention can be administered as a pharmaceutical composition to a subject by various routes including, for example, orally or parenterally, such as intravenously. A pharmaceutical  
25 composition containing the conjugate can be administered by injection or by intubation. The pharmaceutical composition also can be a tumor homing molecule linked to liposomes or other polymer matrices, which can have incorporated therein, an antimicrobial peptide  
30 (Gregoriadis, Liposome Technology, Vol. 1 (CRC Press, Boca Raton, FL 1984), which is incorporated herein by reference). Liposomes, for example, which consist of phospholipids or other lipids, are nontoxic,

physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.

For the therapeutic methods disclosed herein, an effective amount of the homing pro-apoptotic conjugate must be administered to the subject. As used herein, the term "effective amount" means the amount of the conjugate that produces the desired effect. An effective amount often will depend on the particular antimicrobial peptide linked to the tumor homing molecule. An effective amount of a homing pro-apoptotic conjugate in which a tumor homing molecule is linked to a particular antimicrobial peptide can be determined using methods well known to those in the art.

The route of administration of a homing pro-apoptotic conjugate will depend, in part, on the chemical structure of the molecule. Peptides, for example, are not particularly useful when administered orally because they can be degraded in the digestive tract. However, methods for chemically modifying peptides to render them less susceptible to degradation by endogenous proteases or more absorbable through the alimentary tract, including incorporation of D-amino acids, are well known (see, for example, Blondelle et al., *supra*, 1995; Ecker and Crooke, *supra*, 1995; Goodman and Ro, *supra*, 1995). Such modifications can be performed on tumor homing peptides identified by *in vivo* panning as well as on antimicrobial peptides. In addition, methods for preparing libraries of peptidomimetics, which can contain D-amino acids, other non-naturally occurring amino acids, or chemically modified amino acids; or can be organic molecules that mimic the structure of a peptide; or can be peptoids such as vinylogous peptoids, are known in the art and can be

used to identify tumor homing molecules that are stable for oral administration.

A tumor homing peptide can have a linear or cyclic structure. Cysteine residues were included in some peptides, allowing cyclization of the peptides. In particular, peptides containing at least two cysteine residues cyclize spontaneously. In addition, such cyclic peptides also can be active when present in a linear form (see, for example, Koivunen et al., *supra*, 1993). For example, the linear peptide, NGRAHA (SEQ ID NO: 6), also was useful as tumor homing molecule (see Table 2). Thus, in some cases one or more cysteine residues in the tumor homing peptides disclosed herein or otherwise identified as tumor homing peptides can be deleted without significantly affecting the tumor homing activity of the peptide. Methods for determining the necessity of a cysteine residue or of amino acid residues N-terminal or C-terminal to a cysteine residue for tumor homing activity of a peptide of the invention are routine and well known in the art.

As further disclosed herein, some, but not all, tumor homing molecules also can home to angiogenic vasculature that is not contained within a tumor. For example, tumor homing molecules containing either the RGD motif or the GSL motif specifically homed to retinal neovasculature (Smith et al., Invest. Ophthalmol. Vis. Sci. 35:101-111 (1994), which is incorporated herein by reference), whereas tumor homing peptides containing the NGR motif did not accumulate substantially in this angiogenic vasculature. These results indicate that tumor vasculature expresses target molecules that are not substantially expressed by other kinds of angiogenic vasculature. Methods as disclosed herein can be used to

distinguish tumor homing peptides from peptides that home to nontumor angiogenic vasculature. One skilled in the art understands that, preferably, for treatment of a tumor, one administers a conjugate having a tumor homing peptide, which selectively homes to tumor vasculature.

The invention provides chimeric prostate-homing pro-apoptotic peptides which can be used to treat, for example, benign prostate hyperplasia or cancer of the prostate. As disclosed herein, SMSIARL peptide (SEQ ID NO: 207) can selectively localize to prostate tissue, specifically prostate vasculature, when systemically administered (see Example IX.B and IX.E). Furthermore, the prostate homing peptide SMSIARL (SEQ ID NO: 207) can be used to selectively deliver a linked moiety, such as biotin or phage, to prostate tissue. As further disclosed herein, apoptosis was induced in mouse prostate by systemic administration of SMSIARL-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> chimeric peptide; no evidence of apoptosis was observed in non-prostate tissues (see Figure 7 and Example IX.C). The results disclosed herein also demonstrate that administration of SMSIARL-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> chimeric peptide can extend the survival of TRAMP mice, which develop prostate cancer under the influence of a transgene as described in Gingrich et al., Cancer Res. 56: 4096-4102 (1996). Figure 8 shows that SMSIARL-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>-treated mice survived longer than mice treated with vehicle alone, <sub>D</sub>(KLAKLAK)<sub>2</sub> peptide alone, or SMSIARL peptide (SEQ ID NO: 207) alone. Based on these results, the invention provides a chimeric prostate-homing pro-apoptotic peptide as well as methods of using the peptide to treat a patient having prostate cancer as described further below.

Thus, the present invention provides a chimeric prostate-homing pro-apoptotic peptide that contains a prostate-homing peptide linked to an antimicrobial peptide, where the chimeric peptide is selectively  
5 internalized by prostate tissue and exhibits high toxicity thereto, while the antimicrobial peptide has low mammalian cell toxicity when not linked to the prostate-homing peptide. In a chimeric peptide of the invention, the prostate-homing peptide portion can  
10 contain, for example, the sequence SMSIARL (SEQ ID NO: 207) or a functionally equivalent sequence, and the antimicrobial peptide portion can have an amphipathic  $\alpha$ -helical structure such as the sequence (KLAKLAK)<sub>2</sub> (SEQ ID NO: 200), (KLAKKLA)<sub>2</sub> (SEQ ID NO: 201), (KAAKKAA)<sub>2</sub> (SEQ  
15 ID NO: 202) or (KLGKKLG)<sub>3</sub> (SEQ ID NO: 203). In a preferred embodiment, the antimicrobial peptide portion contains the sequence <sub>D</sub>(KLAKLAK)<sub>2</sub>. An exemplary prostate-homing pro-apoptotic peptide is provided herein as SMSIARL-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>.

20 The present invention further provides a method of directing an antimicrobial peptide in vivo to a prostate cancer. The method includes the step of administering a chimeric prostate-homing pro-apoptotic peptide that contains a prostate-homing peptide linked to  
25 an antimicrobial peptide, where the chimeric peptide is selectively internalized by prostate tissue and exhibits high toxicity thereto, while the antimicrobial peptide has low mammalian cell toxicity when not linked to the prostate-homing peptide. In a method of the invention,  
30 the prostate-homing peptide can contain, for example, the sequence SMSIARL (SEQ ID NO: 207) or a functionally equivalent sequence, and the antimicrobial peptide can contain a sequence such as <sub>D</sub>(KLAKLAK)<sub>2</sub>. In a preferred



embodiment, the chimeric prostate-homing pro-apoptotic peptide includes the sequence SMSIARL-GG-D(KLAKLAK)<sub>2</sub>.

Also provided by the invention is a method of inducing selective toxicity *in vivo* in a prostate cancer.

- 5 The method includes the step of administering to a subject containing a prostate cancer a chimeric prostate-homing pro-apoptotic peptide that contains a prostate-homing peptide linked to an antimicrobial peptide, where the chimeric peptide is selectively  
10 internalized by prostate tissue and exhibits high toxicity thereto, while the antimicrobial peptide has low mammalian cell toxicity when not linked to the prostate-homing peptide. The method of inducing selective toxicity *in vivo* in a prostate cancer can be  
15 practiced, for example, with a prostate-homing peptide containing the sequence SMSIARL (SEQ ID NO: 207) or a functionally equivalent sequence. The antimicrobial peptide can include, for example, the sequence  
D(KLAKLAK)<sub>2</sub>. In a preferred embodiment, the chimeric  
20 prostate-homing pro-apoptotic peptide includes the sequence SMSIARL-GG-D(KLAKLAK)<sub>2</sub>.

- In addition, the invention provides a method of treating a patient having prostate cancer by administering to the patient a chimeric prostate-homing  
25 pro-apoptotic peptide of the invention, whereby the chimeric peptide is selectively toxic to the tumor. The chimeric peptide contains a prostate-homing peptide linked to an antimicrobial peptide, and the chimeric peptide is selectively internalized by prostate tissue  
30 and exhibits high toxicity thereto, while the antimicrobial peptide has low mammalian cell toxicity when not linked to the prostate-homing peptide. The prostate-homing peptide portion can contain, for example,

the sequence SMSIARL (SEQ ID NO: 207) or a functionally equivalent sequence, and the antimicrobial peptide portion can contain, for example, the sequence  $_D(KLAKLAK)_2$ . In a preferred embodiment for treating a patient having a prostate tumor, the chimeric peptide contains the sequence SMSIARL-GG- $_D(KLAKLAK)_2$ .

As used herein, the term "prostate-homing peptide" means a peptide that selectively homes *in vivo* to prostate tissue as compared to control tissue, such as brain. Such a peptide generally is characterized by at least a two-fold greater localization to prostatic tissue as compared to a control cell type or tissue. A prostate homing peptide can selectively home, for example, to prostate vasculature as compared to other cell types or other vasculature (see Example IX).

A chimeric peptide of the invention is selectively delivered to the prostate due to the selective homing activity of the prostate-homing peptide portion. A variety of prostate-homing peptides are useful in the invention, including SMSIARL (SEQ ID NO: 207) and VSFLEYR (SEQ ID NO: 222), which were identified by injection of an  $X_7$  library into mice (Table 7) and subsequent *in vivo* panning as described in U.S. Patent No. 5,622,699. The prostate homing peptides SMSIARL (SEQ ID NO: 21) and VSFLEYR (SEQ ID NO: 22) exhibited a 34-fold and 17-fold enrichment, respectively, in prostate as compared to brain.

In one embodiment, the invention relies on a prostate-homing peptide which contains the sequence SMSIARL (SEQ ID NO: 207), or a functionally equivalent sequence. The term "functionally equivalent sequence," as used herein in reference to the sequence SMSIARL (SEQ

ID NO: 207), means a sequence that binds selectively to the endothelium of prostatic blood vessels, as shown in Figure 9 for the sequence SMSIARL (SEQ ID NO: 207), and that functions similarly in that the sequence binds  
5 selectively to the same receptor.

It is understood that the chimeric prostate-homing pro-apoptotic peptides of the invention can be used to induce selective toxicity in a variety of prostatic disorders. Such disorders include benign  
10 nodular hyperplasia of the prostate as well as primary or secondary cancers including clinically apparent as well as subclinical cancers. Cancers to be treated with a chimeric peptide of the invention include prostatic carcinomas such as adenocarcinomas.

15 The following examples are intended to illustrate but not limit the present invention.

#### EXAMPLE I

##### CHARACTERIZATION OF $_D(KLAKLAK)_2$

This example demonstrates that  $_D(KLAKLAK)_2$   
20 preferentially disrupts mitochondrial membrane and induces mitochondria-dependent apoptosis.

The synthetic 14-mer KLAKLAKKLAKLAK (SEQ ID NO: 200), designated  $(KLAKLAK)_2$ , was selected because it  
25 kills bacteria at a concentration two orders of magnitude lower than the concentration required to kill eukaryotic cells (Javadpour et al., J. Med. Chem. 39:3107-3113 (1996)). The all D-enantiomer,  $_D(KLAKLAK)_2$ , was used to avoid degradation by proteases (Bessalle et al.,  
30 FEBS Lett. 274:151-155 (1990); Wade et al., Proc. Natl. Acad. Sci. 87:4761-4765 (1990)).

$\delta$ (KLAKLAK)<sub>2</sub> preferentially disrupts mitochondrial membranes

The ability of  $\delta$ (KLAKLAK)<sub>2</sub> to disrupt mitochondrial membranes preferentially over eukaryotic plasma membranes was evaluated by mitochondrial swelling assays and in a mitochondria-dependent cell-free system of apoptosis, and by cytotoxicity assays.

Mitochondrial swelling assays were performed as follows. Briefly, rat liver mitochondria were prepared as described in Ellerby et al., J. Neurosci. 17:6165-6178 (1997). Peptides were synthesized at higher than 90% purity by HPLC (DLSLARLATARLAI (SEQ ID NO: 204), Coast Scientific, Inc., San Diego, CA; all other peptides, AnaSpec, Inc.). Mitochondria were treated with a concentration of 10  $\mu$ M  $\delta$ (KLAKLAK)<sub>2</sub>, 10  $\mu$ M DLSLARLATARLAI negative control peptide (SEQ ID NO: 204), or 200  $\mu$ M Ca<sup>+2</sup> as a positive control. Peptides were added to mitochondria in a cuvette, and swelling was quantified by measuring the optical absorbance at 520 nm.

20

As shown in Figure 2a, 10  $\mu$ M  $\delta$ (KLAKLAK)<sub>2</sub> induced marked mitochondrial swelling. Mild swelling was evident at a concentration of 3  $\mu$ M, two orders of magnitude less than the concentration required to kill eukaryotic cells (approximately 300  $\mu$ M), as measured by the lethal concentration required to kill 50% of a cell monolayer (LC<sub>50</sub>; Table 1). The non- $\alpha$ -helix forming peptide DLSLARLATARLAI (SEQ ID NO: 204) used as a negative control did not induce mitochondrial swelling. These results demonstrate that  $\delta$ (KLAKLAK)<sub>2</sub> preferentially disrupts mitochondrial membranes as compared to eukaryotic plasma membranes.

30

TABLE 1

LC<sub>50</sub> (μM) FOR EUKARYOTIC CELLS TREATED  
WITH HPP-1 AND D(KLAKLAK)<sub>2</sub>

		DMEC		KS1767	MDA-MB-435	
		Angiostatic	Angiogenic			
			Prolif.	Cord Form	Prolif.	Prolif.
	HPP-1	481	51	34	42	415
5	D(KLAKLAK) <sub>2</sub>	492	346	368	387	333

Results are means of three independent experiments performed in triplicate (t-test,  $P < 0.03$ ).

D(KLAKLAK)<sub>2</sub> induces mitochondrial-dependent apoptosis

The D(KLAKLAK)<sub>2</sub> peptide was assayed for the ability to activate mitochondria-dependent apoptosis in a cell-free system composed of normal mitochondria suspended in normal cytosolic extract (Ellerby et al., J. Neurosci. 17:6165-6178 (1997)). Apoptosis was measured by characteristic caspase-3 processing from an inactive proform to the active protease (Alnemri et al., Cell 87:171 (1996)).

The cell-free apoptosis assays were performed essentially as follows. The cell-free systems were reconstituted as described in Ellerby et al., *supra*, 1997, and, for mitochondria-dependent reactions, rat liver mitochondria were suspended in normal (non-apoptotic) cytosolic extract prepared from dermal microvessel endothelial cells. After adding peptides at a concentration of 100 μM and incubating for 2 hours at 30°C or 37°C, mitochondria were removed by centrifugation, and the supernatant analyzed by SDS/PAGE immunoblotting on a 12% gel (Biorad; Hercules, CA). Proteins were

transferred to PVDF membranes (Biorad) and incubated with anti-caspase-3 antibody (Santa Cruz Biotechnology; Santa Cruz, CA), followed by ECL detection (Amersham; Arlington Heights, IL).

5                   Characteristic caspase-3 processing was measured in dermal microvessel endothelial cell lysates as described in Ellerby et al., *supra*, 1997. Briefly, aliquots of cell lysates (1  $\mu$ l lysate, 8-15 mg/ml) were added to 100  $\mu$ M N-acetyl-Asp-Glu-Val-Asp-pNA (DEVD-pNA; 10 BioMol; 100  $\mu$ l, 100 mM HEPES, 10% sucrose, 0.1% CHAPS, 1 mM DTT, pH 7.0). Hydrolysis of DEVD-pNA was monitored spectrophotometrically (400 nm) at 25°C.

As shown in Figure 2b, lane 4, characteristic caspase-3 processing the active protease was observed in 15 the presence of mitochondria and  $_D(KLAKLAK)_2$ . The non- $\alpha$ -helix forming peptide DLSLARLATARLAI (SEQ ID NO: 204) used as a negative control was inactive when tested in the cell-free system and was not lethal to eukaryotic cells (Figure 2b; see, also, Ellerby et al., *supra*, 20 1997).

In sum, these results indicate that  $_D(KLAKLAK)_2$  preferentially disrupts mitochondrial membranes as compared to eukaryotic plasma membranes and activates mitochondria-dependent apoptosis.

25

## EXAMPLE II

### CHARACTERIZATION OF HPP-1

This example demonstrates that CNGRC-GG- $_D(KLAKLAK)_2$  (HPP-1) inhibits angiogenesis in a tissue culture model.

Chimeras were prepared containing a homing domain linked through a glycylglycine bridge to an antimicrobial peptide. As described above, peptides were synthesized commercially to higher than 90% purity by HPLC by AnaSpec, Inc.

The homing domain was either the cyclic (disulfide bond between cysteines) CNGRC peptide (SEQ ID NO: 8; see Figure 1), or the double cyclic ACDCRGDCFC peptide (SEQ ID NO: 16), both of which have tumor-homing properties (Pasqualini et al., Nature Biotech. 15:542-546 (1997); Arap et al., Science 279:377-380 (1998)) and can be internalized (Arap et al., *supra*, 1998; Hart et al., J. Biol. Chem. 269:12468-12474 (1994); Bretscher et al., EMBO . J. 8:1341-1348 (1989)). Due to the presumed chiral nature of the homing domain-receptor interaction, the homing domain was synthesized from all L amino acids. The glycylglycine bridge was used to couple the homing and antimicrobial domains to impart peptide flexibility and minimize potential steric interactions.

20 Viability of dermal microvessel endothelial cells treated with HPP-1

Efficacy and specificity of HPP-1 were evaluated in a tissue culture model of angiogenesis as described in Goto et al., Lab. Invest. 69:508-517 (1993). During angiogenesis, capillary endothelial cells proliferate and migrate (Risau, Nature 386:671-674 (1997); Zetter, Ann. Rev. Med. 49:407-424 (1998)). Cord formation is a form of migration that is represented in vitro by a change in endothelial cell morphology from the usual "cobblestones" to chains or cords of cells as shown in Figure 3 (see, also, Goto et al., *supra*, 1993).

The effect of HPP-1 was assayed on normal human dermal microvessel endothelial cells (DMECs) under the angiogenic conditions of proliferation and cord formation. In addition, the effect of HPP-1 was assayed  
5 under the angiostatic condition of a monolayer maintained at 100% confluency (as described below).

Briefly, dermal microvessel endothelial cells (DMECs) were grown in CADMEC Growth Media™ (Cell Applications, Inc.; San Diego, CA). Dermal microvessel  
10 endothelial cells were then cultured under three experimental conditions: proliferation, 30% confluency in a growth media supplemented with 500 ng/ml human recombinant vascular endothelial growth factor (VEGF; Pharmingen); no proliferation, 100% confluency in media  
15 formulated to maintain a monolayer; and cord formation, 60% confluency (required for induction) in media formulated to induce cord formation. The KS1767 and MDA-MB-435 cells were cultured as described in Arap et al., *supra*, 1998; Hernier et al., *supra*, 1994).

20 Percent viability and LC<sub>50</sub> (Table 1) were determined by apoptotic morphology as described in Ellerby et al., *J. Neurosci.* 17:6165-6178 (1997). For the percent viability assays, dermal microvessel endothelial cells were treated with 60  $\mu$ M HPP-1 or  
25 control peptide  $\text{p(KLAKLAK)}_2$ . At the indicated time points, cell culture medium was aspirated from adherent cells, and the cells were gently washed once with PBS at 37°C. Subsequently, a 20-fold dilution of the dye mixture (100  $\mu$ g/ml acridine orange and 100  $\mu$ g/ml ethidium  
30 bromide) in PBS was gently pipetted on the cells, which were viewed on an inverted microscope (Nikon TE 300). Cells with nuclei exhibiting margination and condensation of the chromatin and/or nuclear fragmentation (early/mid



apoptosis) or with compromised plasma membranes (late apoptosis) were scored as not viable. At least 500 cells were scored for a given time point in each experiment. Percent viability was calculated relative to untreated controls. The LC<sub>50</sub> for monolayer, proliferation (60% confluency), and cord formation were scored at 72 hours.

As shown in Figure 3, treatment of dermal microvessel endothelial cells with 60 mM HPP-1 led to a decrease in percent viability with time relative to untreated controls, under the conditions of proliferation or cord formation (see Figures 3c and 3d, respectively). In contrast, treatment with the untargeted peptide  $\text{D}(\text{KLAKLAK})_2$  as a negative control led to a negligible loss in viability. Furthermore, the LC<sub>50</sub> for proliferating or migrating dermal microvessel endothelial cells treated with HPP-1 was an order of magnitude lower than the LC<sub>50</sub> for angiostatic dermal microvessel endothelial cells maintained in a monolayer at 100% confluency (Table 1). These results demonstrate preferential killing by HPP-1 under angiogenic conditions as compared to angiostatic conditions.

Various controls also were assayed for an effect on viability of dermal microvessel endothelial cells. The LC<sub>50</sub> for the untargeted control  $\text{D}(\text{KLAKLAK})_2$  under angiogenic conditions was similar to the LC<sub>50</sub> for HPP-1 under angiostatic conditions. Furthermore, a mixture of uncoupled  $\text{D}(\text{KLAKLAK})_2$  and CNGRC (SEQ ID NO: 8), a non-targeted form CARAC-GG- $\text{D}(\text{KLAKLAK})_2$ , and a scrambled form CGRNC-GG- $\text{D}(\text{KLAKLAK})_2$  gave results similar to  $\text{D}(\text{KLAKLAK})_2$ . Moreover, the alternative prototype ACDCRGDCFC-GG- $\text{D}(\text{KLAKLAK})_2$  gave results similar to those for CNGRC-GG- $\text{D}(\text{KLAKLAK})_2$  (HPP-1; data not shown).

Mitochondrial morphology of dermal microvessel  
endothelial cells treated with HPP-1

Mitochondrial morphology of dermal microvessel endothelial cells was assessed in proliferating cells after treatment with 60  $\mu$ M HPP-1, ACDCRGDCFC-GG- $_D$ (KLAKLAK) $_2$  or untargeted  $_D$ (KLAKLAK) $_2$  as follows. Dermal microvessel endothelial cells were stained after 24 and 72 hours treatment with peptide by incubation for 30 min at 37°C with 100 nM mitochondrial stain MitoTracker Red<sup>TM</sup> (Molecular Probes, Inc., Eugene , OR) and 500 nM of the nuclear stain DAPI (Molecular Probes, Inc.). Mitochondria were subsequently visualized using fluorescence microscopy (100x) under an inverted microscope using a triple wavelength filter set (Nikon).

The mitochondria of dermal microvessel endothelial cells treated for 24 hours with  $_D$ (KLAKLAK) $_2$  remained morphologically normal, while those treated with each prototype exhibited altered mitochondrial morphology. In particular, altered mitochondrial morphology was evident in approximately 80% of cells treated with CNGRC-GG- $_D$ (KLAKLAK) $_2$  or ACDCRGDCFC-GG- $_D$ (KLAKLAK) $_2$  before the cells rounded-up. Ultimately, the CNGRC-GG- $_D$ (KLAKLAK) $_2$  (HPP-1) treated dermal microvessel endothelial cells exhibited the classic morphological indicators of apoptosis, including nuclear condensation and fragmentation, as seen at 72 hours (Ellerby et al., *supra*, 1997). Apoptotic cell death was confirmed with by assaying for caspase activity (see Figure 3b; Ellerby et al., *supra*, 1997).

Viability of KS1767 and MDA-MB-435 cells treated with HPP-1

The chimeric HPP-1 peptide was as toxic to  
5 KS1767 cells, which are derived from Kaposi's sarcoma, as  
to the proliferating or migrating dermal microvessel  
endothelial cells (Table 1; Hernier et al., AIDS 8:  
575-581 (1994)). In contrast, HPP-1 was less toxic to  
MDA-MB-435 human breast carcinoma cells by approximately  
10 one order of magnitude (Table 1). KS1767 cells, which  
are of endothelial origin, resemble angiogenic  
endothelial cells and bind the CNGRC peptide (SEQ ID NO:  
8), whereas MDA-MB-435 cells do not (Samaniego et al.,  
Amer. J. Path. 152:1433-1443 (1998); Arap et al., *supra*,  
15 1998).

In sum, these results demonstrate that HPP-1  
induces mitochondrial swelling and apoptosis in dermal  
microvessel endothelial cells.

20

**EXAMPLE III**

IN VIVO ACTIVITY OF HOMING PRO-APOPTOTIC PEPTIDES

This example demonstrates that  
CNGRC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> (HPP-1) inhibits tumor growth and  
prolongs survival of tumor bearing animals. This example  
25 further demonstrates that CDCRGDCFC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>  
inhibits retinal neovascularization.

A. In vivo activity of CNGRC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> (HPP-1)

The activity of HPP-1 was tested *in vivo* using nude mice bearing human MDA-MD-435 breast carcinoma xenografts as follows. Briefly, MDA-MB-435 and  
5 C8161-derived tumor xenografts were established in 2 month-old female nude mice (Jackson Labs; Bar Harbor, ME) as described in Arap et al., *supra*, 1998. After mice were anesthetized with a mixture of 2,2,2-tribromoethanol (Aldrich; Milwaukee, WI) and 2-methyl-butanol (Aldrich)  
10 prepared in distilled water, peptides were administered intravenously through the tail vein at a dose of 250 µg/week/mouse given slowly in a volume of 200 µl. Three-dimensional measurements of tumors were taken by caliper under anesthesia and used to calculate tumor  
15 volume (Pasqualini et al., *supra*, 1996).

As shown in Figure 4a, tumor volume was smaller, on average by one order of magnitude, than in controls, which were a non-targeted CARAC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> and a mixture of uncoupled <sub>D</sub>(KLAKLAK)<sub>2</sub> and CNGRC (SEQ ID  
20 NO: 8) peptides. As further shown in Figure 4b, survival was longer in the HPP-1 treated groups than in control groups. Some of the HPP-1 treated mice outlived control mice by several months, indicating that both primary tumor growth and metastasis were inhibited by HPP-1.  
25 Histopathological analysis revealed pronounced destruction of tumor architecture and widespread cell death in the tumors, demonstrating that the cell death was approximately equally apoptotic and necrotic. In similar experiments, HPP-1 was also effective against  
30 tumors derived from the human melanoma cell line C8161 (Welch et al., Int. J. Cancer 47:227-237 (1991)).

These results indicate that homing pro-apoptotic conjugates such as CNGRC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> (HPP-1) have strong anti-tumor activities *in vivo*.

B. *In vivo* activity of CDCRGDCFC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>

- 5           Retinal angiogenesis was oxygen-induced in newborn mice. Mice were subsequently treated with a single 13 µg intravenous dose (one animal per group) of vehicle; CDCRGDCFC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>; or a control mixture of unconjugated CDCRGDCFC (SEQ ID NO: 1) and <sub>D</sub>(KLAKLAK)<sub>2</sub>.  
10 Four days later, retinal neovessel number was determined for each treatment.

- The results shown in Figure 5 demonstrated that the number of retinal neovessels was reduced in mice treated with the homing pro-apoptotic peptide  
15 CDCRGDCFC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> (column 2; striped bar) as compared to mice treated with vehicle alone (column 1; black bar) or with untargeted pro-apoptotic peptide (column 3; hatched bar). In particular, the angiogenic response in mice treated with the homing pro-apoptotic  
20 peptide CDCRGDCFC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> was only 30-40% of the response seen in the control mice.

- These results show that a homing pro-apoptotic peptide such as CDCRGDCFC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub> can selectively inhibit an angiogenic response such as retinal  
25 neovascularization.

**EXAMPLE IV**  
**IN VIVO PANNING**

This example demonstrates methods for preparing a phage library and screening the library using *in vivo* panning to identify phage expressing tumor homing peptides.

**A. Preparation of phage libraries:**

Phage display libraries were constructed using the fuse 5 vector as described by Koivunen et al. (*supra*, 1995; Koivunen et al., *supra*, 1994b). Libraries encoding peptides designated CX<sub>5</sub>C (SEQ ID NO: 9), CX<sub>6</sub>C (SEQ ID NO: 10), CX<sub>7</sub>C (SEQ ID NO: 11) and CX<sub>3</sub>CX<sub>3</sub>CX<sub>3</sub>C (SEQ ID NO: 12) were prepared, where "C" indicates cysteine and "X<sub>N</sub>" indicates the given number of individually selected amino acids. These libraries can display cyclic peptides when at least two cysteine residues are present in the peptide. In addition, a library that did not contain defined cysteine residues also was constructed. Such a library results in the production primarily of linear peptides, although cyclic peptides also can occur due to random probability.

A biased library based on the sequence CXXXNGRXX (SEQ ID NO: 13) also was constructed. Furthermore, in some cases the CXXXNGRXX (SEQ ID NO: 13) library was further biased by in the incorporation of cysteine residues flanking the NGR sequence, i.e., CXXCNGRCX (SEQ ID NO: 14; see Table 2).

The libraries containing the defined cysteine residues were generated using oligonucleotides constructed such that "C" was encoded by the codon TGT and "X<sub>N</sub>" was encoded by NNK, where "N" is equal molar mixtures of A, C, G and T, and where "K" is equal molar mixtures of G and T. Thus, the peptide represented by CX<sub>5</sub>C (SEQ ID NO: 9) can be represented by an oligonucleotide having the sequence TGT(NNK)<sub>5</sub>TGT (SEQ ID NO: 14). Oligonucleotides were made double stranded by 3 cycles of PCR amplification, purified and ligated to the nucleic acid encoding the gene III protein in the fuse 5 vector such that, upon expression, the peptide is present as a fusion protein at the N-terminus of the gene III protein.

The vectors were transfected by electroporation into MC1061 cells. Bacteria were cultured for 24 hr in the presence of 20 µg/ml tetracycline, then phage were collected from the supernatant by precipitation twice using polyethylene glycol. Each library contained about 5 x 10<sup>9</sup> to 5 x 10<sup>14</sup> transducing units (TU; individual recombinant phage).

#### B. In vivo panning of phage:

Tumors were transplanted into mice as described in Examples V and VI, below. A mixture of phage libraries containing 1 x 10<sup>9</sup> to 1 x 10<sup>14</sup> TU was diluted in 200 µl DMEM and injected into the tail vein of anesthetized mice (AVERTIN (0.015 ml/g); see U.S. Patent No. 5,622,699; Pasqualini and Ruoslahti, *supra*, 1996). After 1-4 minutes, mice were snap frozen in liquid nitrogen. To recover the phage, carcasses were partially thawed at room temperature for 1 hr, tumors and control organs were collected and weighed, then were ground in

1 ml DMEM-PI (DMEM containing protease inhibitors (PI); phenylmethanesulfonyl fluoride (PMSF; 1 mM), aprotinin (20 µg/ml), leupeptin (1 µg/ml)).

Alternatively, following introduction of a  
5 library into a mouse, circulation of the library is terminated by perfusion through the heart. Briefly, mice were anesthetized with AVERTIN, then the heart was exposed and a 0.4 mm needle connected through a 0.5 mm cannula to a 10 cc syringe was inserted into the left  
10 ventricle. An incision was made on the right atrium and 5 to 10 ml of DMEM was slowly administered, perfusing the whole body over about a 5 to 10 min period. Efficiency of the perfusion was monitored directly by histologic analysis.

15 Tumor and organ samples were washed 3 times with ice cold DMEM-PI containing 1% bovine serum albumin (BSA), then directly incubated with 1 ml K91-kan bacteria for 1 hr. Ten ml NZY medium containing 0.2 µg/ml tetracycline (NZY/tet) was added to the bacterial  
20 culture, the mixture was incubated in a 37°C shaker for 1 hr, then 10 µl or 100 µl aliquots were plated in agar plates containing 12.5 µg/ml tetracycline (tet/agar).

Individual colonies containing phage recovered from a tumor were grown for 16 hr in 5 ml NZY/tet. The  
25 bacterial cultures obtained from the individual colonies were pooled and the phage were purified and re-injected into mice as described above for a second round of *in vivo* panning. In general, a third round of panning also was performed. Phage DNA was purified from individual  
30 bacterial colonies obtained from the final round of *in vivo* panning and the DNA sequences encoding the peptides



expressed by selected phage were determined (see Koivunen et al., *supra*, 1994b).

#### EXAMPLE V

##### 5      IDENTIFICATION OF TUMOR HOMING PEPTIDES BY IN VIVO PANNING AGAINST A BREAST TUMOR

This example demonstrates that *in vivo* panning can be performed against a breast tumor to identify tumor homing peptides that home to various tumors.

Human 435 breast carcinoma cells (Price et al.,  
10      Cancer Res. 50:717-721 (1990)) were inoculated into the mammary fat pad of nude mice. When the tumors attained a diameter of about 1 cm, either a phage targeting experiment was performed, in which phage expressing a specific peptide were administered to the tumor bearing  
15      mouse, or *in vivo* panning was performed.

The breast tumor bearing mice were injected with  $1 \times 10^9$  phage expressing a library of CX<sub>3</sub>CX<sub>3</sub>CX<sub>3</sub>C (SEQ ID NO: 12) peptides, where X<sub>3</sub> indicates three groups of independently selected, random amino acids. The phage  
20      were allowed to circulate for 4 min, then the mice were anesthetized, snap frozen in liquid nitrogen while under anesthesia, and the tumor was removed. Phage were isolated from the tumor and subjected to two additional rounds of *in vivo* panning.

TABLE 2

PEPTIDES FROM PHAGE RECOVERED FROM HUMAN BREAST CANCER

	CGRECPRLCQSSC (2*)	CNGRCVSGCAGRC (3)	
	CGEACGGQCALPC (20)	IWSGYGVYW (21)	
5	PSCAYMCIT (22)	WESLYFPRE (23)	
	SKVLYYNWE (24)	CGLMCQGACFDVC (25)	
	CERACRNLCREGC (26)	CPRGCLAVCVSQC (27)	
	CKVCNGRCCG (28)	CEMCNGRCMG (29)	CPLCNGRCAL (30)
	CPTCNGRCVR (31)	CGVCNGRCGL (32)	CEQCNGRCGQ (33)
10	CRNCNGRCEG (34)	CVLCNGRCWS (35)	CVTCNGRCRV (36)
	CTECNGRCQL (37)	CRTCNGRCLE (38)	CETCNGRCVG (39)
	CAVCNGRCGF (40)	CRDLNGRKVM (41)	CSCCNGRCGD (42)
	CWGCNGRCRM (43)	CPLCNGRCAR (44)	CKSCNGRCCLA (45)
	CVPCNGRCHE (46)	CQSCNGRCVR (47)	CRTCNGRCQV (48)
15	CVQCNGRCAL (49)	CRCCNGRCSP (50)	CASNNGRVVL (51)
	CGRCNGRCLL (52)	CWLCNGRCGR (53)	CSKCNGRCGH (54)
	CVWCNGRCGL (55)	CIRCNGRCVS (56)	CGECNGRCVE (57)
	CEGVNGRRLR (58)	CLSCNGRCPS (59)	CEVCNGRCAL (60)
	CGSLVRC (5)	GRSQMQI (61)	HHTRFVS (62)
20	SKGLRHR (63)	VASVSVA (64)	WRVLA AF (65)
	KMGPKVW (66)	IFSGSRE (67)	SPGSWTW (68)
	NPRWFWD (69)	GRWYKWA (70)	IKARASP (71)
	SGWCYRC (72)	ALVGLMR (73)	LWAEMTG (74)
	CWSGVDC (75)	DTLRLRI (76)	SKSSGVS (77)
25	IVADYQR (78)	VWRTGHL (79)	VVDRFPD (80)
	LSMFTRP (81)	GLPVKWS (82)	IMYPGWL (83)
	CVMVRDGDC (84)	CVRIRPC (85)	CQLAAVC (86)
	CGVGSSC (87)	CVSGPRC (88)	CGLSDSC (89)
	CGEGHPC (90)	CYTADPC (91)	CELSLISKC (92)
30	CPEHRSLVC (93)	CLVVHEAAC (94)	CYVELHC (95)
	CWRKFYC (96)	CFWPNRC (97)	CYSYFLAC (98)
	CPRGSRC (99)	CRLGIAC (100)	CDDSWKC (101)
	CAQLLQVSC (102)	CYPADPC (103)	CKALSQAC (104)
	CTDYVRC (105)	CGETMRC (106)	

35 \* - numbers in parentheses indicate SEQ ID NO:.

Following the third round of panning, phage were quantitated and the peptide sequences expressed by the cloned phage were determined. The cloned phage expressed various different peptides, including those shown in Table 2. Similarly, CX<sub>7</sub>C (SEQ ID NO: 11) and CX<sub>5</sub>C (SEQ ID NO: 9) libraries were screened and breast tumor homing peptides were identified (Table 2). These results demonstrate that *in vivo* panning against a breast tumor can identify tumor homing molecules.

10

**EXAMPLE VI**

IN VIVO TARGETING OF A PHAGE EXPRESSING AN  
AN RGD PEPTIDE TO A TUMOR

Human 435 breast carcinoma cells were inoculated into the mammary fat pad of nude mice. When the tumors attained a diameter of about 1 cm, phage expressing a specific RGD-containing peptide were administered to the tumor bearing mouse. Similar results to those discussed below also were obtained with nude mice bearing tumors formed by implantation of human melanoma C8161 cells or by implantation of mouse B16 melanoma cells.

1 x 10<sup>9</sup> phage expressing the RGD-containing peptide, CDCRGDCFC (SEQ ID NO: 1; see, Koivunen et al., *supra*, 1995) or control (insertless) phage were injected intravenously (iv) into the mice and allowed to circulate for 4 min. The mice then were snap frozen or perfused through the heart while under anesthesia, and various organs, including tumor, brain and kidney, were removed and the phage present in the organs was quantitated (see U.S. Patent No. 5,622,699; Pasqualini and Ruoslahti, *supra*, 1996).

Approximately 2-3 times more phage expressing the CDCRGDCFC (SEQ ID NO: 1) peptide were detected in the breast tumor as compared to brain and kidney, indicating the CDCRGDCFC (SEQ ID NO: 1; RGD phage) peptide resulted in selective homing of the phage to the breast tumor. In a parallel study, unselected phage, which express various, diverse peptides, were injected into tumor-bearing mice and various organs were examined for the presence of phage. Far more phage were present in kidney and, to a lesser extent, brain, as compared to the tumor. Thus, the 80-fold more RGD-expressing phage than unselected phage concentrated in the tumor. These results indicate that phage expressing the RGD-containing peptide home to a tumor, possibly due to the expression of the  $\alpha_v\beta_3$  integrin on blood vessels forming in the tumor.

Specificity of the breast tumor homing peptide was demonstrated by competition experiments, in which coinjection of 500  $\mu$ g free peptide, ACDCRGDCFCG (SEQ ID NO: 16; see Pasqualini et al., *supra*, 1997) with the phage expressing the tumor homing peptide reduced the amount of phage in the tumor by about tenfold, whereas coinjection with the inactive control peptide, GRGESP (SEQ ID NO: 17) essentially had no effect. These results demonstrate that phage displaying a peptide that can bind to an integrin expressed on angiogenic vasculature can selectively home *in vivo* to an organ or tissue such as a tumor containing such vasculature.

**EXAMPLE VII****IMMUNOHISTOLOGIC ANALYSIS OF TUMOR HOMING PEPTIDES**

This example provides a method of identifying the localization of tumor homing molecules by immunohistologic examination.

Localization of phage expressing a tumor homing peptide was identified by immunochemical methods in histologic sections obtained either 5 min or 24 hr after administration of phage expressing a tumor homing peptide ("peptide-phage") to a tumor bearing mouse. For samples obtained 5 min following administration of the peptide-phage, mice were perfused with DMEM and various organs, including the tumor, were removed and fixed in Bouin's solution. For samples obtained at 24 hr, no peptide-phage remains in the circulation and, therefore, perfusion was not required. Histologic sections were prepared and reacted with anti-M13 (phage) antibodies (Pharmacia Biotech; see U.S. Patent No. 5,622,699; Pasqualini and Ruoslahti, *supra*, 1996). Visualization of the bound anti-M13 antibody was performed using a peroxidase-conjugated second antibody (Sigma; St. Louis MO) according to the manufacturer's instructions.

As discussed in Example VI, phage expressing the tumor homing peptide, CDCRGDCFC (SEQ ID NO: 1; "RGD phage"), were administered intravenously to mice bearing the breast tumor. In addition, the RGD phage were administered to mice bearing a mouse melanoma or a human Kaposi's sarcoma. Circulation of the phage was terminated and mice were sacrificed as described above and samples of the tumor and of skin adjacent to the tumor, brain, kidney, lung and liver were collected. Immunohistochemical staining for the phage showed

accumulation of the RGD phage in the blood vessels present in the breast tumor as well as in the melanoma and the Kaposi's sarcoma, whereas little or no staining was observed in the control organs.

5                    Similar experiments were performed using phage expressing the tumor homing peptide, CNGRCVSGCAGRC (SEQ ID NO: 3; "NGR phage"), which was identified by *in vivo* panning against a tumor formed by the MDA-MB-435 breast carcinoma. In these experiments, NGR phage or  
10 control phage, which do not express a peptide, were administered to mice bearing tumors formed by the MDA-MB-435 breast carcinoma or by a human SLK Kaposi's sarcoma xenograft, then the mice were sacrificed as described above and tumors were collected as well as  
15 control organs, including brain, lymph node, kidney, pancreas, uterus, mammary fat pad, lung, intestine, skin, skeletal muscle, heart and epithelium of the renal calices, bladder and ureter. Histological samples were prepared and examined by immunostaining as described  
20 above.

                  In samples obtained from mice sacrificed 4 min after administration of the NGR phage, immunostaining of the vasculature of both the breast tumor and the Kaposi's sarcoma was observed. Very little or no staining was  
25 observed in the endothelium of the these tumors in mice administered an insertless control phage. In the samples obtained from mice sacrificed 24 hr after administration of the NGR phage, staining of the tumor samples appeared to have spread outside of the vessels, into the breast  
30 tumor parenchyma and the Kaposi's sarcoma parenchyma. Again, little or no staining was observed in samples prepared from these tumors in mice administered the insertless control phage. In addition, little or no

staining was observed in various control organs in mice administered the NGR phage.

In other experiments, similar results were obtained following administration of phage expressing the NGR tumor homing peptides, NGRAHA (SEQ ID NO: 6) or CVLNGRMEC (SEQ ID NO: 7), to tumor bearing mice. Also, as discussed below, similar results were obtained using phage expressing the GSL tumor homing peptide, CLSGSLSC (SEQ ID NO: 4), which was identified by *in vivo* panning of a melanoma (see Example VIII, below).

These results demonstrate that tumor homing peptides selectively home to tumors, particularly to the vasculature in the tumors and that tumor homing peptides identified, for example, by *in vivo* panning against a breast carcinoma also selectively home to other tumors, including Kaposi's sarcoma and melanoma. In addition, these results demonstrate that immunohistochemical analysis provides a convenient assay for identifying the localization of phage expressing tumor homing peptides.

20

#### EXAMPLE VIII

##### IDENTIFICATION OF TUMOR HOMING PEPTIDES BY IN VIVO PANNING AGAINST A MELANOMA TUMOR

The general applicability of the *in vivo* panning method to identify tumor homing peptides was examined by performing *in vivo* panning against an implanted mouse melanoma tumor.

Mice bearing a melanoma were produced by implantation of B16B15b mouse melanoma cells, which produce highly vascularized tumors. B16B15b mouse melanoma cells were injected subcutaneously into the

mammary fat pad of nude mice (2 months old) and tumors were allowed to grow until the diameter was about 1 cm. *In vivo* panning was performed as disclosed above. Approximately  $1 \times 10^{12}$  transducing units of phage expressing the CX<sub>5</sub>C (SEQ ID NO: 9), CX<sub>6</sub>C (SEQ ID NO: 10) or CX<sub>7</sub>C (SEQ ID NO: 11) library were injected, iv, and allowed to circulate for 4 min. Mice then were snap frozen in liquid nitrogen or perfused through the heart while under anesthesia, tumor tissue and brain (control organ) were removed, and phage were isolated as described above. Three rounds of *in vivo* panning were performed.

TABLE 3

PEPTIDES FROM PHAGE RECOVERED FROM MOUSE B16B15b MELANOMA

	CLSGSLSC (4*)	GICKDDWCQ (107)	TSCDPSLCE (108)
15	KGCGTRQCW (109)	YRCREVLQ (110)	CWGTGLC (111)
	WSCADRTCM (112)	AGCRLKSCA (113)	SRCKTGLCQ (114)
	PICEVSRWC (115)	WTCRASWCS (116)	GRCLLMQCR (117)
	TECDMSRCM (118)	ARCRVDPCV (119)	CIEGVLGGC (120)
	CSVANSC (121)	CSSTMRC (122)	SIDSTTF (123)
20	GPSRVGG (124)	WWSGLEA (125)	LGTDVRQ (126)
	LVGVRL (127)	GRPGDIW (128)	TVWNPVG (129)
	GLLLVVP (130)	FAATSAE (131)	WCCRQFN (132)
	VGFGKAL (133)	DSSLRLP (134)	KLWCAMS (135)
	SLVSFLG (136)	GSFAFLV (137)	IASVRWA (138)
25	TWGHLRA (139)	QYREGLV (140)	QSADRSV (141)
	YMEWTSR (142)	LVRRWYL (143)	TARGSSR (144)
	TTREKNL (145)	PKWLLFS (146)	LRTNVVH (147)
	AVMGLAA (148)	VRNSLRN (149)	

\* - numbers in parentheses indicate SEQ ID NO:.

30

The amino acid sequences were determined for the inserts in 89 cloned phage recovered from the B16B15b



tumors. The peptides expressed by these phage were represented by two predominant sequences, CLSGSLSC (SEQ ID NO: 4; 52% of the clones sequenced) and WGTGLC (SEQ ID NO: 18; 25% of the clones; see Table 3). Reinfection of  
5 phage expressing one of the selected peptides resulted in approximately three-fold enrichment of phage homing to the tumor relative to brain.

Localization of the phage expressing a tumor homing peptide in the mouse organs also was examined by  
10 immunohistochemical staining of the tumor and various other tissues (see Example VII). In these experiments,  $1 \times 10^9$  pfu of a control (insertless) phage or a phage expressing the tumor homing peptide, CLSGSLSC (SEQ ID NO: 4), were injected, iv, into tumor bearing mice and  
15 allowed to circulate for 4 min.

Immunostaining was evident in the melanoma obtained from a mouse injected with phage expressing the CLSGSLSC (SEQ ID NO: 4) tumor homing peptide. Staining of the melanoma generally was localized to the blood  
20 vessels within the tumor, although some staining also was present in the tumor parenchyma. Essentially no staining was observed in a tumor obtained from a mouse injected with the insertless control phage or in skin or in kidney samples obtained from mice injected with either phage.  
25 However, immunostaining was detected in the liver sinusoids and in spleen, indicating that phage can be trapped nonspecifically in organs containing RES.

Using similar methods, *in vivo* panning was performed in mice bearing a SLK human Kaposi's sarcoma.  
30 Tumor homing peptides were identified and are disclosed in Table 4. Together, these results demonstrate that the *in vivo* panning method is a generally applicable method

for screening a phage library to identify phage expressing tumor homing peptides.

**TABLE 4**

PEPTIDES FROM PHAGE RECOVERED FROM HUMAN KAPOSI'S SARCOMA

5	TDCTPSRCT (150*)	SWCQFEKCL (151)	VPCRFRKQCW (152)
	CTAMRNTDC (153)	CRESLKNC (154)	CMEMGVKC (155)
	VTCSRSLMCQ (156)	CNNVGSYC (157)	CGTRVDHC (158)
	CISLDRSC (159)	CAMVSMED (160)	CYLGVSN (161)
	CYLVNVDC (162)	CIRSAVSC (163)	LVCLPPSCE (164)
10	RHCFSQWCS (165)	FYCPGVGCR (166)	ISCAVDACL (167)
	EACEMAGCL (168)	PRCESQLCP (169)	RSCIHKQCP (170)
	QWCSRRWCT (171)	MFCRMRSCD (172)	GICKDLWCQ (173)
	NACESAICG (174)	APCGLLACI (175)	NRCRGVSCT (176)
	FPCEGKKCL (177)	ADCROKPCCL (178)	FGCVMASCR (179)
15	AGCINGLCG (180)	RSCAEPWCY (181)	DTCRALRCN (182)
	KGCGTRQCW (109)	GRCVDGGCT (183)	YRCIARECE (184)
	KRCSSSLCA (185)	ICLLAHCA (186)	QACPMLLCM (187)
	LDCLSELCS (188)	AGCRVESC (189)	HTCLVALCA (190)
	IYCPGQECE (191)	RLCSLYGCV (192)	RKCEVPGCQ (193)
20	EDCTSRFCS (194)	LECVDVDSR (195)	EICVDGLCV (196)
	RWCREKSCW (197)	FRCLERVCT (198)	RPCGDQACE (199)
	CNKTDGDEGVTC (15)		

\* - numbers in parentheses indicate SEQ ID NO:.

**EXAMPLE IX**

25 CHARACTERIZATION OF A CHIMERIC PEPTIDE COMPOSED OF A  
PROSTATE-HOMING PEPTIDE AND  $_D(KLAKLAK)_2$

This example demonstrates that the chimeric peptide SMSIARL-GG- $_D(KLAKLAK)_2$  can selectively induce apoptosis in prostate tissue following systemic

administration and can prolong survival of animals with experimental prostate cancer.

#### A. Isolation of prostate homing peptides

An X<sub>7</sub> library was injected into mice, and 5 sequences isolated that were preferentially found in prostate as compared to brain as described in WO 99/46284. The prostate homing peptides SMSIARL (SEQ ID NO: 207) and VSFLEYR (SEQ ID NO: 222) exhibited a 34-fold and 17-fold enrichment, respectively, in prostate 10 as compared to brain. Additional prostate homing sequences identified by *in vivo* panning are shown in Table 5.

**TABLE 5**  
15 PEPTIDES FROM PHAGE RECOVERED FROM PROSTATE

	EVQSAKW (209)	KRVYVLG (210)
	GRLSVQV (211)	WKPASLS (212)
	FAVRVVG (213)	LVRPLEG (214)
20	GFYRMLG (215)	EGRPMVY (216)
	GSRSLGA (217)	RVWQGDV (218)
	GDELLA (219)	FVWLVS (220)
	GSEPMFR (221)	VSFLEYR (222)
	WHQPL (223)	SMSIARL* (207)
25	RGRWLAL* (224)	QVEEFPC (225)
	LWLSGNW (226)	GPMLSVM (227)
	WTFLERL (228)	VLPGGQW (229)
	REVKES (230)	RTPAAVM (231)
	GEWLGEC (232)	PNPLMPL (233)
30	SLWYLGA (234)	YVGGWEL (235)

Parentheses contain SEQ ID NO:.

\* indicates sequences isolated more than once.

B. Prostate homing of prostate-homing peptide biotin  
conjugates

Using *in vivo* screening of a heptapeptide phage library, a prostate-homing peptide has been identified  
5 that concentrates in the prostate 35-fold more than in various other tissues. This phage displays the peptide SMSIARL (SEQ ID NO: 207). Coinjecting synthetic SMSIARL peptide (SEQ ID NO: 207) inhibited the prostate-selective homing of phage bearing SMSIARL (SEQ ID NO: 207).  
10 Furthermore, antibody staining of tissue sections showed that SMSIARL (SEQ ID NO: 207) phage localized to prostate tissue, but not to other tissues after an intravenous injection of the phage into mice. Control phage also did not accumulate in the prostate. SMSIARL (SEQ ID NO: 207)  
15 phage also homed to rat prostate tissue.

As shown in Figure 6, the biotin-conjugated SMSIARL (SEQ ID NO: 207) synthetic peptide was shown to home to the prostate. Briefly, one mg of biotin-conjugated prostate-homing peptide SMSIARL (SEQ ID  
20 NO: 207), or biotin-labeled control peptide CARAC (SEQ ID NO: 208), was injected intravenously into a mouse, which was sacrificed 10 minutes later. The prostate and other tissues were collected, sectioned and processed for staining with avidin-peroxidase. Biotin staining was  
25 found mostly in the lumen of the glands, rather than in the vasculature, as soon as 10 minutes after systemic injection of the conjugate. These results indicate that the SMSIARL (SEQ ID NO: 207) peptide, as well as other moieties attached to it such as phage or biotin,  
30 translocates to the prostate epithelium and then into the glandular lumen.

### C. Induction of prostate-selective apoptosis

The ability of the SMSIARL peptide (SEQ ID NO: 207) to deliver a pro-apoptotic peptide,  $_D(KLAKLAK)_2$ , to the prostate was analyzed. Briefly,

5 SMSIARL-GG- $_D(KLAKLAK)_2$  chimeric peptide or control material was administered as a single dose of 250  $\mu$ g peptide/mouse, and TUNEL staining was performed on tissues obtained 24 hours later. As shown in Figure 7, mice injected with the SMSIARL-GG- $_D(KLAKLAK)_2$  chimera

10 showed increased apoptosis in their prostates and, in particular, in capillary endothelium and the basal myoepithelial cells of prostate glands. There was no evidence of increased apoptosis in other tissues such as the testis, kidney or brain. Apoptosis was not observed

15 in negative control mice treated with 250  $\mu$ g of an unconjugated mixture of SMSIARL (SEQ ID NO: 207) and  $_D(KLAKLAK)_2$ .

### D. SMSIARL-GG- $_D(KLAKLAK)_2$ treatment of TRAMP mice

TRAMP mice develop prostate cancer under the

20 influence of a transgene as described in Gingrich et al., *supra*, 1996. SMSIARL-GG- $_D(KLAKLAK)_2$  chimeric peptide was assayed for the ability to suppress cancer development in the TRAMP mice. Treatment was initiated at 12 weeks of age with mice (10 per group) receiving

25 SMSIARL-GG- $_D(KLAKLAK)_2$  peptide or control peptide at 250  $\mu$ g/dose every other week for a total of 10 doses. Four mice, which had no visible tumor, were eliminated from the SMSIARL-GG- $_D(KLAKLAK)_2$  group after dying within minutes after the injection. As shown in Figure 8,

30 SMSIARL-GG- $_D(KLAKLAK)_2$ -treated mice survived longer than mice treated with controls, which were vehicle,  $_D(KLAKLAK)_2$  peptide alone, or SMSIARL peptide (SEQ ID NO:

207) alone. Thus, treatment of TRAMP mice with targeted pro-apoptotic SMSIARL-GG-D(KLAKLAK)<sub>2</sub> compound over a period of several months resulted in an apparent increase in survival of the treated mice relative to control mice.

5 E. Prostate-homing SMSIARL (SEQ ID NO: 207) phage bind to human prostate vasculature

A human prostate tissue section containing both normal and cancerous tissue was overlaid with 10<sup>9</sup> TU SMSIARL phage (SEQ ID NO: 207), and the binding of the  
10 phage was detected with anti-phage antibody and peroxidase staining. As shown in Figure 9, SMSIARL (SEQ ID NO: 207) phage bind to the endothelium of human prostate blood vessels (see panels a and b). No endothelial staining was seen with phage that contain no  
15 peptide insert (panel c). Furthermore, the SMSIARL (SEQ ID NO: 207)-phage staining was inhibited when soluble SMSIARL peptide SEQ ID NO: 207 was included in the overlay at 0.3 mg/ml. The results shown in Figure 9 indicate that at least some tumors retain the receptor  
20 for the homing peptide. Furthermore, peptide SEQ ID NO: 207 can bind to vessels in intraprostatic cancer, while blood vessels in several other human tissues were not stained by the SMSIARL (SEQ ID NO: 207) phage.

All journal article, reference, and patent  
25 citations provided above, in parentheses or otherwise, whether previously stated or not, are incorporated herein by reference.

Although the invention has been described with reference to the examples above, it should be understood  
30 that various modifications can be made without departing

from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

We claim:

1. A chimeric prostate-homing pro-apoptotic peptide, comprising a prostate-homing peptide linked to an antimicrobial peptide,  
5           said chimeric peptide selectively internalized by prostate tissue and exhibiting high toxicity thereto, and  
              said antimicrobial peptide having low mammalian cell toxicity when not linked to said prostate-homing  
10 peptide.
2. The chimeric peptide of claim 1, wherein said prostate-homing peptide comprises the sequence SMSIARL : (SEQ ID NO: 207), or a functionally equivalent sequence.
3. The chimeric peptide of claim 1, wherein said  
15 antimicrobial peptide has an amphipathic  $\alpha$ -helical structure.
4. The chimeric peptide of claim 1, wherein said antimicrobial peptide comprises a sequence selected from  
20 the group consisting of:  
                  (KLAKLAK)<sub>2</sub> (SEQ ID NO: 200);  
                  (KLAKKLA)<sub>2</sub> (SEQ ID NO: 201);  
                  (KAAKKAA)<sub>2</sub> (SEQ ID NO: 202); and  
                  (KLGKKLG)<sub>3</sub> (SEQ ID NO: 203).
- 25       5. The chimeric peptide of claim 1, wherein said antimicrobial peptide comprises the sequence <sub>D</sub>(KLAKLAK)<sub>2</sub>.
6. The chimeric peptide of claim 5, comprising the sequence SMSIARL-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>.



7. The chimeric peptide of claim 6, consisting of the sequence SMSIARL-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>.

8. A method of directing an antimicrobial peptide *in vivo* to a prostate cancer, comprising administering  
5 the chimeric peptide of claim 1.

9. The method of claim 8, wherein said prostate-homing peptide comprises the sequence SMSIARL (SEQ ID NO: 207), or a functionally equivalent sequence.

10. The method of claim 8, wherein said  
10 antimicrobial peptide comprises the sequence <sub>D</sub>(KLAKLAK)<sub>2</sub>.

11. The method of claim 10, wherein said chimeric peptide comprises the sequence SMSIARL-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>.

12. The method of claim 11, wherein said chimeric peptide is SMSIARL-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>.

15 13. A method of inducing selective toxicity *in vivo* in a prostate cancer, comprising administering the chimeric peptide of claim 1 to a subject having prostate cancer.

14. The method of claim 13, wherein said  
20 prostate-homing peptide comprises the sequence SMSIARL (SEQ ID NO: 207), or a functionally equivalent sequence.

15. The method of claim 13, wherein said antimicrobial peptide comprises the sequence <sub>D</sub>(KLAKLAK)<sub>2</sub>.

16. The method of claim 15, wherein said chimeric  
25 peptide comprises the sequence SMSIARL-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>.

17. The method of claim 16, wherein said chimeric peptide is SMSIARL-GG-D(KLAKLAK)<sub>2</sub>.

18. A method of treating a patient having a prostate cancer, comprising administering the chimeric  
5 peptide of claim 1 to said patient, whereby said chimeric peptide is selectively toxic to said tumor.

19. The method of claim 18, wherein said prostate-homing peptide comprises the sequence SMSIARL (SEQ ID NO: 207), or a functionally equivalent sequence.

10 20. The method of claim 18, wherein said antimicrobial peptide comprises the sequence D(KLAKLAK)<sub>2</sub>.

21. The method of claim 20, wherein said chimeric peptide comprises the sequence SMSIARL-GG-D(KLAKLAK)<sub>2</sub>.

22. The method of claim 21, wherein said chimeric  
15 peptide is SMSIARL-GG-D(KLAKLAK)<sub>2</sub>.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6






Figure 7




Figure 8




Figure 9

## SEQUENCE LISTING

<110> The Burnham Institute  
Ruoslahti, Erkki  
Pasqualini, Renata  
Wadiah, Arap  
Bredesen, Dale E.  
Ellerby, H. Michael

<120> Chimeric Prostate-Homing Peptides With  
Pro-Apoptotic Activity

<130> FP-LJ 4386

<150> US 09/489,582  
<151> 2000-01-21

<160> 235

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 1  
Cys Asp Cys Arg Gly Asp Cys Phe Cys  
1 5

<210> 2  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 2  
Cys Gly Arg Glu Cys Pro Arg Leu Cys Gln Ser Ser Cys  
1 5 10

<210> 3  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 3

Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys  
1 5 10

<210> 4

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 4

Cys Leu Ser Gly Ser Leu Ser Cys  
1 5

<210> 5

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 5

Cys Gly Ser Leu Val Arg Cys  
1 5

<210> 6

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 6

Asn Gly Arg Ala His Ala  
1 5

<210> 7

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 7

Cys Val Leu Asn Gly Arg Met Glu Cys  
1 5

<210> 8  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 8  
Cys Asn Gly Arg Cys  
1 5

<210> 9

<220>  
<223> synthetic peptide

<400> 9  
000

<210> 10

<220>  
<223> synthetic peptide

<400> 10  
000

<210> 11

<220>  
<223> synthetic peptide

<400> 11  
000

<210> 12  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<221> VARIANT  
<222> (1)...(13)  
<223> Xaa = Any Amino Acid

<400> 12  
Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys

1

5

10

&lt;210&gt; 13

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(9)

&lt;223&gt; Xaa = Any Amino Acid

&lt;400&gt; 13

Cys Xaa Xaa Xaa Asn Gly Arg Xaa Xaa

1

5

&lt;210&gt; 14

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(9)

&lt;223&gt; Xaa = Any Amino Acid

&lt;400&gt; 14

Cys Xaa Xaa Cys Asn Gly Arg Cys Xaa

1

5

&lt;210&gt; 15

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 15

Cys Asn Lys Thr Asp Gly Asp Glu Gly Val Thr Cys

1

5

10

&lt;210&gt; 16

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 16

Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly  
1 5 10

&lt;210&gt; 17

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 17

Gly Arg Gly Glu Ser Pro  
1 5

&lt;210&gt; 18

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 18

Trp Gly Thr Gly Leu Cys  
1 5

&lt;210&gt; 19

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 19

Gly Ala Cys Val Phe Ser Ile Ala His Glu Cys Gly Ala  
1 5 10

&lt;210&gt; 20

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide



&lt;400&gt; 20

Cys Gly Glu Ala Cys Gly Gly Gln Cys Ala Leu Pro Cys  
1 5 10

&lt;210&gt; 21

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 21

Ile Trp Ser Gly Tyr Gly Val Tyr Trp  
1 5

&lt;210&gt; 22

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 22

Pro Ser Cys Ala Tyr Met Cys Ile Thr  
1 5

&lt;210&gt; 23

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 23

Trp Glu Ser Leu Tyr Phe Pro Arg Glu  
1 5

&lt;210&gt; 24

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 24

Ser Lys Val Leu Tyr Tyr Asn Trp Glu  
1 5

<210> 25  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 25  
Cys Gly Leu Met Cys Gln Gly Ala Cys Phe Asp Val Cys  
1 5 10

<210> 26  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 26  
Cys Glu Arg Ala Cys Arg Asn Leu Cys Arg Glu Gly Cys  
1 5 10

<210> 27  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 27  
Cys Pro Arg Gly Cys Leu Ala Val Cys Val Ser Gln Cys  
1 5 10

<210> 28  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 28  
Cys Lys Val Cys Asn Gly Arg Cys Cys Gly  
1 5 10

<210> 29

<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 29  
Cys Glu Met Cys Asn Gly Arg Cys Met Gly  
1 5 10

<210> 30  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 30  
Cys Pro Leu Cys Asn Gly Arg Cys Ala Leu  
1 5 10

<210> 31  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 31  
Cys Pro Thr Cys Asn Gly Arg Cys Val Arg  
1 5 10

<210> 32  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 32  
Cys Gly Val Cys Asn Gly Arg Cys Gly Leu  
1 5 10

<210> 33  
<211> 10  
<212> PRT  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 33

Cys	Glu	Gln	Cys	Asn	Gly	Arg	Cys	Gly	Gln
1				5					10

&lt;210&gt; 34

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 34

Cys	Arg	Asn	Cys	Asn	Gly	Arg	Cys	Glu	Gly
1				5					10

&lt;210&gt; 35

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 35

Cys	Val	Leu	Cys	Asn	Gly	Arg	Cys	Trp	Ser
1				5					10

&lt;210&gt; 36

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 36

Cys	Val	Thr	Cys	Asn	Gly	Arg	Cys	Arg	Val
1				5					10

&lt;210&gt; 37

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 37

Cys Thr Glu Cys Asn Gly Arg Cys Gln Leu  
1 5 10

&lt;210&gt; 38

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 38

Cys Arg Thr Cys Asn Gly Arg Cys Leu Glu  
1 5 10

&lt;210&gt; 39

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 39

Cys Glu Thr Cys Asn Gly Arg Cys Val Gly  
1 5 10

&lt;210&gt; 40

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 40

Cys Ala Val Cys Asn Gly Arg Cys Gly Phe  
1 5 10

&lt;210&gt; 41

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 41

Cys Arg Asp Leu Asn Gly Arg Lys Val Met

1 5 10

<210> 42  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 42  
Cys Ser Cys Cys Asn Gly Arg Cys Gly Asp  
1 5 10

<210> 43  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 43  
Cys Trp Gly Cys Asn Gly Arg Cys Arg Met  
1 5 10

<210> 44  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 44  
Cys Pro Leu Cys Asn Gly Arg Cys Ala Arg  
1 5 10

<210> 45  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 45  
Cys Lys Ser Cys Asn Gly Arg Cys Leu Ala  
1 5 10

<210> 46  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 46  
Cys Val Pro Cys Asn Gly Arg Cys His Glu  
1 5 10

<210> 47  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 47  
Cys Gln Ser Cys Asn Gly Arg Cys Val Arg  
1 5 10

<210> 48  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 48  
Cys Arg Thr Cys Asn Gly Arg Cys Gln Val  
1 5 10

<210> 49  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 49  
Cys Val Gln Cys Asn Gly Arg Cys Ala Leu  
1 5 10

<210> 50  
<211> 9  
<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 50

Cys Arg Cys Cys Asn Gly Arg Cys Ser

1

5

<210> 51

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 51

Cys Ala Ser Asn Asn Gly Arg Val Val Leu

1

5

10

<210> 52

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 52

Cys Gly Arg Cys Asn Gly Arg Cys Leu Leu

1

5

10

<210> 53

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 53

Cys Trp Leu Cys Asn Gly Arg Cys Gly Arg

1

5

10

<210> 54

<211> 10

<212> PRT

<213> Artificial Sequence

<220>



<223> synthetic peptide

<400> 54

Cys Ser Lys Cys Asn Gly Arg Cys Gly His  
1 5 10

<210> 55

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 55

Cys Val Trp Cys Asn Gly Arg Cys Gly Leu  
1 5 10

<210> 56

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 56

Cys Ile Arg Cys Asn Gly Arg Cys Ser Val  
1 5 10

<210> 57

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 57

Cys Gly Glu Cys Asn Gly Arg Cys Val Glu  
1 5 10

<210> 58

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 58

Cys Glu Gly Val Asn Gly Arg Arg Leu Arg  
1 5 10

<210> 59

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 59

Cys Leu Ser Cys Asn Gly Arg Cys Pro Ser  
1 5 10

<210> 60

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 60

Cys Glu Val Cys Asn Gly Arg Cys Ala Leu  
1 5 10

<210> 61

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 61

Gly Arg Ser Gln Met Gln Ile  
1 5

<210> 62

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 62

His His Thr Arg Phe Val Ser  
1 5

<210> 63  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 63  
Ser Lys Gly Leu Arg His Arg  
1 5

<210> 64  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 64  
Val Ala Ser Val Ser Val Ala  
1 5

<210> 65  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 65  
Trp Arg Val Leu Ala Ala Phe  
1 5

<210> 66  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 66  
Lys Met Gly Pro Lys Val Trp  
1 5

<210> 67  
<211> 7

<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 67  
Ile Phe Ser Gly Ser Arg Glu  
1 5

<210> 68  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide  
  
<400> 68  
Ser Pro Gly Ser Trp Thr Trp  
1 5

<210> 69  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 69  
Asn Pro Arg Trp Phe Trp Asp  
1 5

<210> 70  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 70  
Gly Arg Trp Tyr Lys Trp Ala  
1 5

<210> 71  
<211> 7  
<212> PRT  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 71

Ile Lys Ala Arg Ala Ser Pro

1

5

&lt;210&gt; 72

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 72

Ser Gly Trp Cys Tyr Arg Cys

1

5

&lt;210&gt; 73

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 73

Ala Leu Val Gly Leu Met Arg

1

5

&lt;210&gt; 74

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 74

Leu Trp Ala Glu Met Thr Gly

1

5

&lt;210&gt; 75

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 75

Cys Trp Ser Gly Val Asp Cys

1

5

&lt;210&gt; 76

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 76

Asp Thr Leu Arg Leu Arg Ile

1

5

&lt;210&gt; 77

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 77

Ser Lys Ser Ser Gly Val Ser

1

5

&lt;210&gt; 78

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 78

Ile Val Ala Asp Tyr Gln Arg

1

5

&lt;210&gt; 79

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 79

Val Trp Arg Thr Gly His Leu

1

5

<210> 80  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 80  
Val Val Asp Arg Phe Pro Asp  
1 5

<210> 81  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 81  
Leu Ser Met Phe Thr Arg Pro  
1 5

<210> 82  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 82  
Gly Leu Pro Val Lys Trp Ser  
1 5

<210> 83  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 83  
Ile Met Tyr Pro Gly Trp Leu  
1 5

<210> 84

<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 84  
Cys Val Met Val Arg Asp Gly Asp Cys  
1 5

<210> 85  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 85  
Cys Val Arg Ile Arg Pro Cys  
1 5

<210> 86  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 86  
Cys Gln Leu Ala Ala Val Cys  
1 5

<210> 87  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 87  
Cys Gly Val Gly Ser Ser Cys  
1 5

<210> 88  
<211> 7  
<212> PRT  
<213> Artificial Sequence



<220>  
<223> synthetic peptide

<400> 88  
Cys Val Ser Gly Pro Arg Cys  
1 5

<210> 89  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 89  
Cys Gly Leu Ser Asp Ser Cys  
1 5

<210> 90  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 90  
Cys Gly Glu Gly His Pro Cys  
1 5

<210> 91  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 91  
Cys Tyr Thr Ala Asp Pro Cys  
1 5

<210> 92  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

&lt;400&gt; 92

Cys Glu Leu Ser Leu Ile Ser Lys Cys

1

5

&lt;210&gt; 93

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 93

Cys Pro Glu His Arg Ser Leu Val Cys

1

5

&lt;210&gt; 94

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 94

Cys Leu Val Val His Glu Ala Ala Cys

1

5

&lt;210&gt; 95

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 95

Cys Tyr Val Glu Leu His Cys

1

5

&lt;210&gt; 96

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 96

Cys Trp Arg Lys Phe Tyr Cys

1

5

&lt;210&gt; 97

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 97

Cys Phe Trp Pro Asn Arg Cys

1

5

&lt;210&gt; 98

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 98

Cys Tyr Ser Tyr Phe Leu Ala Cys

1

5

&lt;210&gt; 99

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 99

Cys Pro Arg Gly Ser Arg Cys

1

5

&lt;210&gt; 100

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 100

Cys Arg Leu Gly Ile Ala Cys

1

5

<210> 101  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 101  
Cys Asp Asp Ser Trp Lys Cys Pro  
1 5

<210> 102  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 102  
Cys Ala Gln Leu Leu Gln Val Ser Cys  
1 5

<210> 103  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 103  
Cys Tyr Pro Ala Asp Pro Cys  
1 5

<210> 104  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 104  
Cys Lys Ala Leu Ser Gln Ala Cys  
1 5

<210> 105  
<211> 7  
<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 105

Cys Thr Asp Tyr Val Arg Cys  
1 5

<210> 106

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 106

Cys Gly Glu Thr Met Arg Cys  
1 5

<210> 107

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 107

Gly Ile Cys Lys Asp Asp Trp Cys Gln  
1 5

<210> 108

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 108

Thr Ser Cys Asp Pro Ser Leu Cys Glu  
1 5

<210> 109

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 109

Lys Gly Cys Gly Thr Arg Gln Cys Trp  
1 5

<210> 110

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 110

Tyr Arg Cys Arg Glu Val Leu Cys Gln  
1 5

<210> 111

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 111

Cys Trp Gly Thr Gly Leu Cys  
1 5

<210> 112

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 112

Trp Ser Cys Ala Asp Arg Thr Cys Met  
1 5

<210> 113

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 113

Ala Gly Cys Arg Leu Lys Ser Cys Ala  
1 5

<210> 114  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 114  
Ser Arg Cys Lys Thr Gly Leu Cys Gln  
1 5

<210> 115  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 115  
Pro Ile Cys Glu Val Ser Arg Cys Trp  
1 5

<210> 116  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 116  
Trp Thr Cys Arg Ala Ser Trp Cys Ser  
1 5

<210> 117  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 117  
Gly Arg Cys Leu Leu Met Gln Cys Arg  
1 5

<210> 118  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 118  
Thr Glu Cys Asp Met Ser Arg Cys Met  
1 5

<210> 119  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 119  
Ala Arg Cys Arg Val Asp Pro Cys Val  
1 5

<210> 120  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 120  
Cys Ile Glu Gly Val Leu Gly Gly Cys  
1 5

<210> 121  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 121  
Cys Ser Val Ala Asn Ser Cys  
1 5

<210> 122  
<211> 7



<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 122  
Cys Ser Ser Thr Met Arg Cys  
1 5

<210> 123  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide  
  
<400> 123  
Ser Ile Asp Ser Thr Thr Phe  
1 5

<210> 124  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide  
  
<400> 124  
Gly Pro Ser Arg Val Gly Gly  
1 5

<210> 125  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide  
  
<400> 125  
Trp Trp Ser Gly Leu Glu Ala  
1 5

<210> 126  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 126  
Leu Gly Thr Asp Val Arg Gln  
1 5

<210> 127  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 127  
Leu Val Gly Val Arg Leu Leu  
1 5

<210> 128  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 128  
Gly Arg Pro Gly Asp Ile Trp  
1 5

<210> 129  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 129  
Thr Val Trp Asn Pro Val Gly  
1 5

<210> 130  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 130  
Gly Leu Leu Leu Val Val Pro  
1 5

<210> 131  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 131  
Phe Ala Ala Thr Ser Ala Glu  
1 5

<210> 132  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 132  
Trp Cys Cys Arg Gln Phe Asn  
1 5

<210> 133  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 133  
Val Gly Phe Gly Lys Ala Leu  
1 5

<210> 134  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 134  
Asp Ser Ser Leu Arg Leu Pro  
1 5

<210> 135  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 135  
Lys Leu Trp Cys Ala Met Ser  
1 5

<210> 136  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 136  
Ser Leu Val Ser Phe Leu Gly  
1 5

<210> 137  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 137  
Gly Ser Phe Ala Phe Leu Val  
1 5

<210> 138  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 138  
Ile Ala Ser Val Arg Trp Ala  
1 5

<210> 139

<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 139  
Thr Trp Gly His Leu Arg Ala  
1 5

<210> 140  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide  
  
<400> 140  
Gln Tyr Arg Glu Gly Leu Val  
1 5

<210> 141  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide  
  
<400> 141  
Gln Ser Ala Asp Arg Ser Val  
1 5

<210> 142  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 142  
Tyr Met Phe Trp Thr Ser Arg  
1 5

<210> 143  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 143

Leu Val Arg Arg Trp Tyr Leu  
1 5

<210> 144

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 144

Thr Ala Arg Gly Ser Ser Arg  
1 5

<210> 145

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 145

Thr Thr Arg Glu Lys Asn Leu  
1 5

<210> 146

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 146

Pro Lys Trp Leu Leu Phe Ser  
1 5

<210> 147

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

&lt;400&gt; 147

Leu Arg Thr Asn Val Val His

1

5

&lt;210&gt; 148

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 148

Ala Val Met Gly Leu Ala Ala

1

5

&lt;210&gt; 149

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 149

Val Arg Asn Ser Leu Arg Asn

1

5

&lt;210&gt; 150

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 150

Thr Asp Cys Thr Pro Ser Arg Cys Thr

1

5

&lt;210&gt; 151

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 151

Ser Trp Cys Gln Phe Glu Lys Cys Leu

1

5

&lt;210&gt; 152

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 152

Val Pro Cys Arg Phe Lys Gln Cys Trp

1

5

&lt;210&gt; 153

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 153

Cys Thr Ala Met Arg Asn Thr Asp Cys

1

5

&lt;210&gt; 154

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 154

Cys Arg Glu Ser Leu Lys Asn Cys

1

5

&lt;210&gt; 155

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 155

Cys Met Glu Met Gly Val Lys Cys

1

5



<210> 156  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 156  
Val Thr Cys Arg Ser Leu Met Cys Gln  
1 5

<210> 157  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 157  
Cys Asn Asn Val Gly Ser Tyr Cys  
1 5

<210> 158  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 158  
Cys Gly Thr Arg Val Asp His Cys  
1 5

<210> 159  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 159  
Cys Ile Ser Leu Asp Arg Ser Cys  
1 5

<210> 160  
<211> 8  
<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 160

Cys Ala Met Val Ser Met Glu Asp

1

5

<210> 161

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 161

Cys Tyr Leu Gly Val Ser Asn Cys

1

5

<210> 162

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 162

Cys Tyr Leu Val Asn Val Asp Cys

1

5

<210> 163

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 163

Cys Ile Arg Ser Ala Val Ser Cys

1

5

<210> 164

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 164

Leu Val Cys Leu Pro Pro Ser Cys Glu  
1 5

<210> 165

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 165

Arg His Cys Phe Ser Gln Trp Cys Ser  
1 5

<210> 166

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 166

Phe Tyr Cys Pro Gly Val Gly Cys Arg  
1 5

<210> 167

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 167

Ile Ser Cys Ala Val Asp Ala Cys Leu  
1 5

<210> 168

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 168

Glu Ala Cys Glu Met Ala Gly Cys Leu  
1 5

<210> 169  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 169  
Pro Arg Cys Glu Ser Gln Leu Cys Pro  
1 5

<210> 170  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 170  
Arg Ser Cys Ile Lys His Gln Cys Pro  
1 5

<210> 171  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 171  
Gln Trp Cys Ser Arg Arg Trp Cys Thr  
1 5

<210> 172  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 172  
Met Phe Cys Arg Met Arg Ser Cys Asp  
1 5

<210> 173  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 173  
Gly Ile Cys Lys Asp Leu Trp Cys Gln  
1 5

<210> 174  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 174  
Asn Ala Cys Glu Ser Ala Ile Cys Gly  
1 5

<210> 175  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 175  
Ala Pro Cys Gly Leu Leu Ala Cys Ile  
1 5

<210> 176  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 176  
Asn Arg Cys Arg Gly Val Ser Cys Thr  
1 5

<210> 177  
<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 177

Phe Pro Cys Glu Gly Lys Lys Cys Leu  
1 5

<210> 178

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 178

Ala Asp Cys Arg Gln Lys Pro Cys Leu  
1 5

<210> 179

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 179

Phe Gly Cys Val Met Ala Ser Cys Arg  
1 5

<210> 180

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 180

Ala Gly Cys Ile Asn Gly Leu Cys Gly  
1 5

<210> 181

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 181

Arg Ser Cys Ala Glu Pro Trp Cys Tyr

1

5

<210> 182

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 182

Asp Thr Cys Arg Ala Leu Arg Cys Asn

1

5

<210> 183

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 183

Gly Arg Cys Val Asp Gly Gly Cys Thr

1

5

<210> 184

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 184

Tyr Arg Cys Ile Ala Arg Glu Cys Glu

1

5

<210> 185

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

&lt;400&gt; 185

Lys Arg Cys Ser Ser Ser Leu Cys Ala  
1 5

&lt;210&gt; 186

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 186

Ile Cys Leu Leu Ala His Cys Ala  
1 5

&lt;210&gt; 187

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 187

Gln Ala Cys Pro Met Leu Leu Cys Met  
1 5

&lt;210&gt; 188

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 188

Leu Asp Cys Leu Ser Glu Leu Cys Ser  
1 5

&lt;210&gt; 189

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 189

Ala Gly Cys Arg Val Glu Ser Cys  
1 5



<210> 190  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 190  
His Thr Cys Leu Val Ala Leu Cys Ala  
1 5

<210> 191  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 191  
Ile Tyr Cys Pro Gly Gln Glu Cys Glu  
1 5

<210> 192  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 192  
Arg Leu Cys Ser Leu Tyr Gly Cys Val  
1 5

<210> 193  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 193  
Arg Lys Cys Glu Val Pro Gly Cys Gln  
1 5

<210> 194

<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 194  
Glu Asp Cys Thr Ser Arg Phe Cys Ser  
1 5

<210> 195  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 195  
Leu Glu Cys Val Val Asp Ser Cys Arg  
1 5

<210> 196  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 196  
Glu Ile Cys Val Asp Gly Leu Cys Val  
1 5

<210> 197  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 197  
Arg Trp Cys Arg Glu Lys Ser Cys Trp  
1 5

<210> 198  
<211> 9  
<212> PRT  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 198

Phe Arg Cys Leu Glu Arg Val Cys Thr  
1 5

&lt;210&gt; 199

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 199

Arg Pro Cys Gly Asp Gln Ala Cys Glu  
1 5

&lt;210&gt; 200

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 200

Lys Leu Ala Lys Leu Ala Lys Lys Leu Ala Lys Leu Ala Lys  
1 5 10

&lt;210&gt; 201

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 201

Lys Leu Ala Lys Lys Leu Ala Lys Leu Ala Lys Lys Leu Ala  
1 5 10

&lt;210&gt; 202

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 202

Lys Ala Ala Lys Lys Ala Ala Lys Ala Ala Lys Lys Ala Ala  
1 5 10

&lt;210&gt; 203

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 203

Lys Leu Gly Lys Lys Leu Gly Lys Leu Gly Lys Lys Leu Gly Lys Leu  
1 5 10 15  
Gly Lys Lys Leu Gly  
20

&lt;210&gt; 204

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 204

Asp Leu Ser Leu Ala Arg Leu Ala Thr Ala Arg Leu Ala Ile  
1 5 10

&lt;210&gt; 205

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 205

000

&lt;210&gt; 206

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 206

000

&lt;210&gt; 207

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<220>  
<223> synthetic peptide

<400> 207  
Ser Met Ser Ile Ala Arg Leu  
1 5

<210> 208  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 208  
Cys Ala Arg Ala Cys  
1 5

<210> 209  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 209  
Glu Val Gln Ser Ala Lys Trp  
1 5

<210> 210  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 210  
Lys Arg Val Tyr Val Leu Gly  
1 5

<210> 211  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 211  
Gly Arg Leu Ser Val Gln Val  
1 5

<210> 212  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 212  
Trp Lys Pro Ala Ser Leu Ser  
1 5

<210> 213  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 213  
Phe Ala Val Arg Val Val Gly  
1 5

<210> 214  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 214  
Leu Val Arg Pro Leu Glu Gly  
1 5

<210> 215  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 215  
Gly Phe Tyr Arg Met Leu Gly  
1 5

<210> 216  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 216  
Glu Gly Arg Pro Met Val Tyr  
1 5

<210> 217  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 217  
Gly Ser Arg Ser Leu Gly Ala  
1 5

<210> 218  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 218  
Arg Val Trp Gln Gly Asp Val  
1 5

<210> 219  
<211> 6  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 219  
Gly Asp Glu Leu Leu Ala  
1 5

<210> 220

<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> synthetic peptide  
  
<400> 220  
Phe Val Trp Leu Val Gly Ser  
1 5

<210> 221  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 221  
Gly Ser Glu Pro Met Phe Arg  
1 5

<210> 222  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 222  
Val Ser Phe Leu Glu Tyr Arg  
1 5

<210> 223  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 223  
Trp His Gln Pro Leu  
1 5

<210> 224  
<211> 7  
<212> PRT  
<213> eArtificial Sequence



<220>

<223> synthetic peptide

<400> 224

Arg Gly Arg Trp Leu Ala Leu  
1 5

<210> 225

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 225

Gln Val Glu Glu Phe Pro Cys  
1 5

<210> 226

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 226

Leu Trp Leu Ser Gly Asn Trp  
1 5

<210> 227

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 227

Gly Pro Met Leu Ser Val Met  
1 5

<210> 228

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

&lt;400&gt; 228

Trp Thr Phe Leu Glu Arg Leu  
1 5

&lt;210&gt; 229

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 229

Val Leu Pro Gly Gly Gln Trp  
1 5

&lt;210&gt; 230

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 230

Arg Glu Val Lys Glu Ser  
1 5

&lt;210&gt; 231

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 231

Arg Thr Pro Ala Ala Val Met  
1 5

&lt;210&gt; 232

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 232

Gly Glu Trp Leu Gly Glu Cys

1

5

&lt;210&gt; 233

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 233

Pro Asn Pro Leu Met Pro Leu

1

5

&lt;210&gt; 234

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 234

Ser Leu Trp Tyr Leu Gly Ala

1

5

&lt;210&gt; 235

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic peptide

&lt;400&gt; 235

Tyr Val Gly Gly Trp Glu Leu

1

5

## INTERNATIONAL SEARCH REPORT

Inter national Application No  
PCT/US 01/01362

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07K14/47 A61K47/48 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, CHEM ABS Data, MEDLINE, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1999 ELLERBY H MICHAEL ET AL: "Anti-cancer activity of targeted pro-apoptotic peptides." Database accession no. PREV199900484607 XP002164829 abstract &amp; NATURE MEDICINE, vol. 5, no. 9, 1999, pages 1032-1038, ISSN: 1078-8956</p> <p style="text-align: center;">--- -/--</p>	1-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

5 April 2001

Date of mailing of the international search report

30.04.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Döpfer, K-P

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/01362

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99 46284 A (BURNHAM INST) 16 September 1999 (1999-09-16) claims 1-5 tables 1,7 page 54, line 28 -page 55, line 3 page 56, line 18 -page 57, line 3	1-22
P,X	WO 00 42973 A (BURNHAM INST) 27 July 2000 (2000-07-27) the whole document	1-22
A	WO 99 13329 A (BURNHAM INST) 18 March 1999 (1999-03-18) claims 9-36	1-22
A	WO 98 10795 A (BURNHAM INST) 19 March 1998 (1998-03-19) page 4, line 11 -page 5, line 26 claims	1-22
A	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996 JAVADPOUR MARYAM M ET AL: "De novo antimicrobial peptides with low mammalian cell toxicity." Database accession no. PREV199699130909 XP002164830 abstract & JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 16, 1996, pages 3107-3113, ISSN: 0022-2623	1,3-7
A	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997 JAVADPOUR MARYAM M ET AL: "Self-assembly of designed antimicrobial peptides in solution and micelles." Database accession no. PREV199799701983 XP002164831 abstract & BIOCHEMISTRY, vol. 36, no. 31, 1997, pages 9540-9549, ISSN: 0006-2960	1,3-7

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/01362

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.1

Although claims 8-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter-  
national Application No  
PCT/US 01/01362

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9946284 A	16-09-1999	US 6174687 B AU 3078399 A EP 1062232 A	16-01-2001 27-09-1999 27-12-2000
WO 0042973 A	27-07-2000	AU 3348600 A	07-08-2000
WO 9913329 A	18-03-1999	US 6180084 B AU 9477398 A EP 1015884 A	30-01-2001 29-03-1999 05-07-2000
WO 9810795 A	19-03-1998	AU 4412297 A EP 0927045 A JP 2001501600 T	02-04-1998 07-07-1999 06-02-2001